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ABSTRACT 
 
Dopamine D2 Receptor Priming Enhances Dopaminergic Response to Amphetamine in 
the Nucleus Accumbens:  Role of the D1 and D2 Receptors.   
by 
 
Kimberly Norris Huggins  
 
In past work, we have shown neonatal quinpirole (dopamine D2/D3 agonist) treatment produces 
a significant increase in dopamine D2 receptor sensitivity, a phenomenon known as D2 receptor 
priming. Dopamine D2 receptor priming is common in psychosis. Male and female rats were 
administered quinpirole (1mg/kg) or saline from postnatal days 1-11 and raised to adulthood 
(P60). As adults, rats were administered d-amphetamine sulfate (1mg/kg) or saline every other 
day for 14 days. Approximately 10 min before each amphetamine or saline injection, animals 
were administered the D1 antagonist SCH 23390 (0.1 mg/kg), the D2 antagonist eticlopride (0.1 
mg/kg) or saline. After both injections, rats were placed in a locomotor arena and activity was 
analyzed for a 10-min period. Results indicated that D2-priming enhanced locomotor activation 
effects to amphetamine in both males and females, with females demonstrating higher levels of 
behavioral activation. SCH 23390 blocked amphetamine sensitization in both males and 
females to levels below saline controls, whereas eticlopride was more effective in blocking 
amphetamine sensitization in males as compared to females, although eticlopride did block 
elevations of behavioral activation in D2-primed males and females. Seven to 10 days after 
sensitization, microdialysis was performed and amphetamine produced a five-fold increase in 
dopamine overflow in the nucleus accumbens compared to non D2-primed rats administered 
amphetamine.  Both D1 and D2 antagonism were effective at blocking amphetamine-induced 
increases in dopamine overflow.   These results show that neonatal quinpirole treatment 
enhances behavioral activation and dopamine overflow, but there appear to be sex differences 
in the D2 as compared to D1 response to behavioral activation produced by amphetamine. 
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CHAPTER 1 
INTRODUCTION 
 Substance use disorder comorbidity in mental illness is widespread, impacting up 
to 50% of patient populations (Siegfried 1998).  Schizophrenia is one of the most 
common dually diagnosed mental illnesses (Cuffel 1996). Dopamine has been 
implicated in psychosis as being increased in its activity (Schmitt et al. 2009). This 
increased activity has been debated, but most agree that this neurotransmitter plays a 
primary role in both motor behavior and drug reinforcement.  In our laboratory, we have 
used a rodent model of increased dopaminergic activity to analyze drug abuse. This 
model is focused on increasing the sensitivity of dopamine D2-like receptors in the 
brain, that is accomplished through developmental treatment with a dopamine D2/D3 
agonist quinpirole.  Previous work using this model has shown a potentiated effect of 
amphetamine on dopamine overflow within the dorsal striatum (Nowak et al. 2001). This 
effect is consistent with findings in schizophrenia (Abi Dargham et al. 1996; Laurelle et 
al. 1996). Thus, these results suggest that psychotics who use amphetamine may 
demonstrate a sensitized dopamine response to amphetamine. If this is the case, then 
this increased dopamine response may be producing a stronger euphoric reaction to 
stimulant drugs in this population, and this may be the basis for the increased usage of 
these drugs in this population.  
This study uses these past findings as a springboard to analyze the effects of 
subchronic amphetamine treatment on locomotor sensitization and accumbal dopamine 
as well as to identify sex differences on these measures. In addition, the roles of 
dopamine D1 and D2 dopamine receptors in sensitization and the dopaminergic 
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response to amphetamine are studied. These findings may lead to identifying receptor 
mechanisms of this effect, be the first study to analyze the roles of D1 and D2 receptors 
in both males and females in this phenomenon, that may lead to further understanding 
the significant health problem of substance abuse in psychosis.  
Dopamine D2 Receptor Priming Model 
Kostrzewa and colleagues have shown that quinpirole, a dopamine D2/D3 
receptor agonist, administered during neonatal development results in increases in 
dopamine D2 receptor sensitivity throughout the animal‟s lifetime. This is a phenomenon 
that has been referred to as priming of the D2 receptor.  Previous work has shown that 
quinpirole treatment from postnatal days 1-11, 1-21, or 21-35 results in an increase of 
dopamine D2 receptor sensitivity that persists throughout the animal‟s lifetime 
(Kostrzewa et al. 1990, 1991, 1993a, 1993b, 1995).  This change is independent of a 
change in D2 receptor number.  In recent work, we have shown that the neonatal 
quinpirole treatment model has produced several behavioral changes that are 
consistent with findings in schizophrenics.  
 First, as mentioned above, acute amphetamine administration to adult rats 
neonatally treated with quinpirole produced a robust increase in dopamine overflow in 
the striatum greater than an increase seen by amphetamine administration alone 
(Nowak et al. 2001).  This is consistent with findings from clinical studies using 
functional magnetic resonance imaging (fMRI), positron emission tomography (PET), 
and single positron emission computer tomography (SPECT) in schizophrenic patients 
that have shown a pronounced increase of amphetamine-induced dopamine release in 
the dorsal striatum as well as a decrease of amphetamine-induced dopamine depletion 
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in drug-naïve schizophrenic patients, indicating a regulatory problem with dopaminergic 
neurotransmission (Lanzenberger and Kasper 2005, Laruelle, et al. 2005). 
 Second, a hallmark of psychosis is a deficit in sensorimotor gating, that is most 
commonly analyzed using the behavioral paradigm prepulse inhibition (PPI). PPI is a 
psychophysiological index of sensorimotor gating.  One of the more consistent 
behavioral findings in schizophrenics is that PPI is impaired, that has also been 
suggested to be related to cognitive impairments known to exist in this population 
(Geyer 1998). In medicated schizophrenia patients, greater PPI impairment during the 
attended prepulse has been associated with heightened positive symptoms related to 
the disturbance (Dawson et al. 2000).   We have shown that in previous work that adult 
rats that were neonatally treated with quinpirole demonstrated deficits in sensorimotor 
gating as tested by PPI (Maple 2005). 
 Third, neonatal quinpirole treatments have been shown to produce long-term 
cognitive impairment in both adolescents and adulthood (Brown et al. 2002; 2004; 
2005).  Cognitive impairment is present in schizophrenia and has been suggested to be 
the „core‟ of behavioral deficits present in the disorder (Elvevag and Goldman 2000).  
This suggestion follows the discovery that 94% of patients with schizophrenia have 
neurocognitive deficits in the areas of memory, attention, and executive function and 
may help predict the functional outcome in schizophrenia (Waldo et al. 1994; Green 
1998).  Often, these deficits constitute one of the key features in a schizophrenia 
diagnosis (Peuskens et al. 2005).  
 Fourth, possibly the most important neurophysiological finding consistent 
with psychosis is that neonatal quinpirole treatment produces a significant decrease in 
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RGS9 expression in the nucleus accumbens, striatum, and frontal cortex of adult rats 
(Maple et al. 2007).  RGS9 is a regulator of G-protein signaling at the D2 receptor, and 
when active RGS9 increases the rate of termination of events at the D2 receptor, 
ultimately resulting in a lower activity in the D2 receptor (Rahman et al. 2003). Thus, a 
decrease in RGS9 expression is consistent with an increased signaling at the D2 
receptor. Importantly, significant decreases in RGS9 have been shown in these same 
brain areas post-mortem in human psychotic patients (Seeman et al. 2007).  
 Fifth, subchronic treatment with the atypical antipsychotic olanzapine has been 
shown to alleviate cognitive deficits and long-term priming of the D2 receptor produced 
by neonatal quinpirole treatment (Thacker et al. 2006).  Olanzapine is in the atypical 
class of antipsychotics and blocks the D2 receptor with some affinity as well at the 5-
HT2 receptor.  Olanzapine is one of the most often prescribed antipsychotics for 
schizophrenia. Our laboratory has shown that sub-chronic olanzapine treatment given 
twice daily for 1 month in adulthood modestly alleviated deficits in Morris water maze 
performance produced by neonatal quinpirole treatment (Thacker et al. 2006). 
Importantly, this treatment also alleviated the significant increase in yawning produced 
in rats neonatally treated with quinpirole to control levels after a 7-day washout. 
Yawning behavior is a dopamine D2/D3 receptor mediated event (Cooper, et al. 1989; 
Collins, et al. 2005). These data demonstrate that not only is D2-priming likely primarily 
responsible for these behavioral effects, but that antipsychotic treatments are effective 
in alleviating cognitive impairment, that is also consistent with clinical findings in 
schizophrenics (Gurpegui et al. 2007).  
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Sixth, another neurochemical consistency in this model is that neonatal 
quinpirole treatments have been shown to result in neurotrophic factor abnormalities 
comparable to observations in human schizophrenic patients.  Studies from this lab 
have shown a significant decrease in nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) protein in the hippocampus of D2-primed animals as 
compared to control treated animals. Further, significant decreases in hippocampal 
NGF and BDNF protein produced by neonatal quinpirole treatment were reversed by 
olanzapine, and brain tissue was not taken until after an 8-day washout.  Interestingly, 
sub-chronic olanzapine treatment failed to alleviate significant decreases of genetic 
expression of NGF or BDNF in the hippocampus or frontal cortex as measured through 
real-time PCR (RT-PCR; Brown et al. 2008), suggesting that the positive effects of 
olanzapine on neurotrophic factors in this model may be focused on changes in protein 
and not genetic expression. This is consistent with findings that have shown non-
medicated schizophrenic patients have an overall decrease in NGF and BDNF 
expression, hypothetically involved in neurodevelopmental abnormalities in the 
hippocampus and frontal cortex known to be present in schizophrenia (Aloe et al. 2001, 
Parikh et al. 2003).  
These six consistencies demonstrate the validity of the model relative to 
psychosis. However, this model should be used with some caution. Although an 
increase in dopamine D2 receptor sensitivity is a hallmark of psychosis, it is not the only 
change responsible for the array of behavioral abnormalities known to exist within this 
disorder. For example, it is also well-known that there is hypoactivity at the 
glutamatergic N-methyl-D-aspartate (NMDA) receptor that is important for many of the 
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behavioral and neurochemical abnormalities mentioned above (Labrie and Roder, 
2009), and may be important in the increased substance abuse within this population. 
Further, there are also important changes in the serotonergic system that also may play 
a role in substance abuse in psychosis as well, and we do not yet know whether these 
neurotransmitter systems are also disrupted in the same manner within this model. 
Regardless, increases in D2 receptor sensitivity are a hallmark of psychosis, and we 
have shown several important consistencies between this model and the human 
condition. 
Psychosis 
 Psychotic symptoms can occur in several behavioral disorders including 
schizophrenia, bipolar disorder, obsessive-compulsive disorder, degenerative brain 
disease, as well as following the abuse of steroids. While these diseases exhibit unique 
characteristics, one common biomarker is a putative increase in the high-affinity states 
of dopamine D2 receptors in the central nervous system as a property of psychosis 
(CNS; Seeman et al. 2005). The D2 dopamine receptor, originally denoted as the 
antipsychotic receptor, has been examined for changes in density following various 
treatments, most commonly denervation of the neostriatum and long-term 
administration of antipsychotics (Seeman et al. 1980; Schwarting and Huston 1996,). 
Most importantly, increases in D2 receptor sensitivity are the basis of the dopamine 
hypothesis of schizophrenia, as all antipsychotic drugs block the D2 receptor.  
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Dopamine Hypothesis of Schizophrenia 
 The first formulation of the dopamine (DA) hypothesis resulted from early 
observations that activation of the dopamine system by psychostimulants produced a 
behavioral phenomenon that is consistent with psychosis, and that dopamine 
antagonists relieved this psychotic state (Rossum 1966).  These observations led to the 
hypothesis that hyperactivity of DA transmission was responsible for the disorder.  The 
classic dopamine hypothesis was further bolstered from the correlation between clinical 
doses of antipsychotic drugs and their potency at blocking DA D2 receptors as well as 
the psychotogenic effects of DA-enhancing drugs (Creese et al. 1976; Lieberman et al. 
1987; Seeman 1987). 
The current hypothesis suggests that an imbalance in DA with hyperactive 
subcortical mesolimbic projections results in hyperstimulation of D2 receptors. This 
increased sensitivity of D2 receptor causes positive symptoms and hypoactive 
mesocortical DA projections to the prefrontal cortex (PFC) results in hypostimulation of 
D1 receptors, that ultimately results in negative symptoms and cognitive impairment 
(Tzschentke 2001).  Weinberger has suggested that the two areas of DA imbalance 
may be related because a deficiency in mesocortical DA function may translate into 
disinhibition of mesolimbic DA activity (1987).  
 Dopamine has been a major focus of the research involving the mechanisms of 
schizophrenia.  Much of the literature suggests a combined impact of glutamatergic and 
dopaminergic systems as the mechanism underlying psychosis, and some studies   
have focused on dysfunction in the glutamate system.  While each system has shown 
results lending merit towards and understanding of the disease, it remains difficult to 
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reconcile the hypoglutamatergic and hyperdopaminergic hypotheses.  It is most 
plausible that the heterogenous symptomology of the disease arise from different 
neurotransmitter systems.  The dopamine hypothesis is no longer the only accepted 
theory as the basis of schizophrenia but still holds validity in the study of many aspects 
of the disease. 
Modeling Psychosis 
Using Animal Models and Their Importance 
 A recent focus of neuroscience research and of the National Institutes of Health 
has been on the formation of models of human diseases (NIH Roadmap, 2005).  
Overall, animal models add value in basic sciences research by allowing investigators 
to elucidate aspects of complex disease or mechanistic pathways.  Animal models are 
limited by the inability to study the long-term progression of a disease and the lack of 
direct homology between animal systems and the human system (Woodruff and 
Baisden 1994). However, animal models may be useful for development and discovery 
of new and more effective treatments for neurological disorders (Woodruff & Baisden 
1994).  In many cases, animal models of neurological disease and dysfunction are used 
to model one aspect of the disorder whether it be behavioral, neurochemical, or 
neuropathological. This can be extremely useful because it can be informative about the 
contribution of this behavioral or neurochemical abnormality to the disease or disorder, 
although the entire disorder is not modeled in the animal. McKinney and Brunney (1969) 
proposed three criteria for validating an animal model of similar inducing conditions, 
similar behavioral states, and common mechanisms in an animal model. The D2-
priming model used in this study reaches all three of these criteria, as mentioned above. 
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McKinney and Brunney (1969) concluded that the higher number of criteria the model 
achieves means that the model has increased validity. Therefore, the model used here 
has increased validity relative to the psychotic state, although we have not yet shown 
whether there are changes in non-dopaminergic systems that are consistent with the 
disorder. Therefore, to research a clinical condition in humans, an animal model that 
does not necessarily have all aspects of the disorder can be used for a more thorough 
examination of the disease. 
 Animal Models of Psychosis 
Modeling schizophrenia and/or psychosis poses several difficulties as a result of 
the heterogeneity of the presentation of symptoms.  Animal models are used in studying 
schizophrenia, psychosis as an aspect of mental illness, drug-induced psychoses, and 
bipolar disorder that may include a psychotic component.  The psychotic component of 
schizophrenia has garnered much attention adding to the understanding of psychosis in 
general.  Schizophrenia is a severe and chronic mental illness affecting approximately 
1% of the population.  Symptoms of schizophrenia typically emerge during adolescence 
or early adulthood (American Psychiatric Association, 2008).  Symptoms are usually 
classified into three categories:  positive (hallucinations, delusions, thought 
disorganization), negative (anhedonia, social withdrawal), and cognitive (deficits in 
attention and memory) (Carpenter and Buchanan, 1994).  Hallucinations can be 
auditory, visual, tactile, or olfactory in nature.  Auditory hallucinations include hearing 
voices and sounds that are not audible to outside observers (American Psychiatric 
Association Diagnostic and Statistical Manual 2000).  Negative symptoms include a 
flattened affect or lack of emotion, intonation or facial expression, as well as anhedonia 
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(absence of pleasure and lack of motivation or ability to follow through with plans).  
Clinical diagnoses recognize impaired social relationships, difficulty in maintaining self-
care, and impaired social and professional interactions as part of the disorder.  Previous 
research suggests that alterations in several neurotransmitter systems are involved in 
the pathophysiological process leading to the expression of these symptoms, though no 
clear etiology of schizophrenia has been shown.  
Other Rodent Models of Schizophrenia 
Several animal models have been used to investigate aspects of schizophrenia. 
The importance of animal research is evident in the ability to generalize findings using 
animal subjects to the human health condition. Generalization of schizophrenic research 
from animal to human is possible through using behavioral tasks with specific task 
demands, testing parameters, and mechanisms of the behavioral deficits involved in the 
disorder. There have been several attempts to model schizophrenia using rodent 
models. All of these models have clinical relevance to the disorder through mimicking 
neurochemical abnormalities known to be present in schizophrenia. However, it is also 
important to realize that all of these models have weaknesses that relate to the 
complexity of the neurochemical aberrations in this disorder. 
NMDA Receptor Model 
A primary abnormality in schizophrenia is related to the glutamatergic system.  
The glutamate hypothesis suggests that glutamatergic dysfunction is associated with 
the NMDA receptor.  Research has found that a glutamatergic receptor subtype, the N-
methyl-D-aspartate (NMDA) receptor, is less responsive in schizophrenics than it is in 
controls (Tsai and Coyle 2002, Coyle 2006). Based on NMDA hypofunction, 
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researchers have focused on producing NMDA hypofunction through acute 
administration of phencyclidine (PCP) or ketamine, that are both noncompetitive 
antagonists of the N-methyl-D-aspartate (NMDA) glutamate receptor. Studies have 
shown that NMDA receptor hypofunction results in positive and negative symptoms 
similar to those found in schizophrenia as well as cognitive deficits in normal humans 
(Snyder 1980, Javitt and Zukin 1991, Tamminga 1998).  NMDA receptors are a major 
subtype of glutamate receptors that mediate slow excitatory postsynaptic potentials 
(EPSPs) that are considered critical for the expression of behaviors including 
associative learning, working memory, and attention, functions that are impaired in 
schizophrenia (Blair et al. 2001).    PCP has also been shown in rats and humans to 
closely mimic the positive, negative, and cognitive symptoms observed in schizophrenia 
(Krystal et al. 1994, Carlsson et al. 2004, Lisman et al. 2008).  Neuronal 
synchronization, that is thought to depend partly on glutamatergic regulation over 
GABAergic neurons, is impaired in schizophrenia and correlates with perceptual, 
speech, and other cognitive processes (Spencer et al. 2003, Ford et al. 2007, Lewis et 
al. 2005, Mohler 2007, Gaspar et al. 2009).  Using a novel object recognition paradigm, 
rats treated with PCP were shown to produce robust reductions in time spent with the 
novel object versus the familiar object, a measure of working memory (Grayson, et al. 
2007).  The novel object recognition task, that is used to measure working memory, was 
developed based on the natural propensity of rats to explore novel objects (Ennaceur 
and Delacour 1988).  A reduction in working memory following PCP administration 
helps to establish some validity of the model in terms of investigating cognitive deficits 
that may exist in schizophrenia. This model would not withstand the criteria for face 
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validity as many of the symptoms of schizophrenia are subjective in nature and cannot 
truly be replicated in an animal model.  However, glutamatergic manipulations have 
value as a predictive model as such manipulations induce behavioral or neurochemical 
changes similar to schizophrenia and are alleviated by similar therapeutic treatments.  
Psychostimulant Model 
Acute administration of psychostimulants is known to produce a robust increase 
in dopamine release, and increased dopaminergic activity as a result of psychostimulant 
treatment was the original basis of the dopamine hypothesis of schizophrenia (Duncan 
et al. 1999).  Increases in dopamine function, as mentioned above, are known to be 
common in schizophrenia. In the psychostimulant model, animals are tested while under 
the influence of the drug to analyze behavioral changes related to robust increases in 
the dopamine system (Tilson & Rech 1973, Lacriox et al. 2000).   
Two behavioral measures used in an effort to model schizophrenia that seem to 
have clinical relevance are latent inhibition and prepulse inhibition (PPI).  Latent 
inhibition (LI) is a process by that exposure to a stimulus of little or no consequence 
prevents conditioned associations with that stimulus from being formed.  Latent 
inhibition has been interpreted as a representation of the lack of the ability to ignore 
irrelevant information, a deficit observed in schizophrenic patients (Solomon et al. 1981, 
Killcross et al. 1994).  Disruption in LI has been demonstrated in schizophrenia (Gray et 
al. 1992, 1995, Lipp et al. 1992).  The operational processes can be viewed as 
analogous across species (Lubow and Gewritz 1995).  Prepulse inhibition (PPI) is a 
psychophysiological index of sensorimotor gating that has been used with schizophrenic 
patients.  PPI is defined as the reduction of the amplitude of the startle reflex (usually 
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the eyeblink reflex in humans) when a “prepulse” that is non-startling precedes the 
startle pulse (Blumenthal 1999).  PPI has been found to be impaired in schizophrenic 
patients. For example, using treatments of amphetamine with and without DA 
antagonists, it was shown that the medial prefrontal cortex is involved in mediating 
prepulse inhibition but is not involved in latent inhibition (Lacroix et al. 2000).  Thus, 
cortical changes proposed in schizophrenia may be modeled using PPI measurements 
but not LI.  Although these treatments are helpful in elucidating the effects of short-term 
increases in DA release, they are unable to recreate the long-term dopaminergic effects 
seen in schizophrenia.  Therefore, the acute administration of a pharmacological 
substance may be useful as a predictive model but does not meet the constraints for 
face validity or construct validity.  
Neonatal Ventral Hippocampal Lesion (NVHL) Model 
Likely the most prominently used model of schizophrenia has focused on 
neonatal damage of the ventral hippocampus in rats (Lipska et al. 1993, Chambers et 
al. 1996, Wan et al. 1996, Brake et al. 1999, Grecksch et al. 1999). Past results have 
shown that lateral ventricles are larger and that the hippocampus is smaller in volume in 
schizophrenics.  The main objective of this model is to disrupt hippocampal 
development that is a hallmark of neuropathology known to be present in schizophrenia 
(Falkai and Bogerts 1986; Bogerts et al. 1990; Suddath et al. 1990; Eastwood and 
Harrison 1995; 1998; Weinberger 1999). The disruption of hippocampal development 
also results in the changes of the cortical and subcortical circuitry of brain areas that 
make connections to the hippocampal formation.  These neonatal lesions are intended 
to involve regions of the hippocampus that directly project to the prefrontal cortex, 
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including the ventral hippocampus proper and ventral subiculum that corresponds to the 
anterior hippocampus in humans (Jay et al. 1989; Carr and Sesack 1996).   These 
lesions produce changes in hippocampal-frontal cortex connectivity consistent with 
schizophrenia as well as changes in behavioral deficits in latent inhibition, prepulse 
inhibition, social responses, and cognitive performance (Swerdlow et al. 1996, Lipska et 
al. 1995, Chambers et al. 1996, Grecksch et al. 1999). Further, these changes do not 
emerge until after adolescence, consistent with the presentation of schizophrenia in 
humans (Lipska et al. 1993, Chambers et al. 1996, Becker et al. 1999, Lipska et al. 
1995).   The lesions result in the clear destruction of ventral portions of the 
hippocampus including parts of the CA1, CA2, and CA3 regions and portions of the 
ventral subiculum (Swerdlow et al. 2001).  A major weakness of this model involves the 
blatant neuronal damage created by the lesion.  This disconnection of neurons is not 
exhibited in schizophrenia and the impact of such disruption outside of the targeted 
effects may be yet unknown.   
Comorbidity of Substance Abuse 
Drug addiction is viewed as a complex neuroadaptive process through that drugs 
of abuse alter cellular and molecular aspects of neural function to increase or decrease 
the responsiveness of various behavioral effects through their mediating circuits (White 
2002).  The dopaminergic system is most directly implicated in the positive reinforcing 
effects of all drugs of abuse.  The ability of addictive drugs to enhance dopamine 
neurotransmission, primarily in the mesolimbic dopaminergic system, has been 
documented widely across various classes of abused drugs (Wise and Bozarth 1987, 
Koob 1992, White 1996, Spanagel and Weiss 1999).   
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Substance Abuse in Schizophrenia  
Substance abuse in schizophrenics carries consequences that further impact 
schizophrenic patients.  Research has shown that among individuals diagnosed with 
schizophrenia between 33% and 66% meet the criteria for at least one substance 
related disorder in their lifetime (Meuser et al. 1992).  Schizophrenic patients with 
concurrent substance abuse experience more frequent hospitalization episodes 
(Swofford et al. 2000).  The interactions of the drugs of abuse with the neuropathology 
of schizophrenia exacerbate symptoms and interfere with drug treatments (Burnette et 
al. 1997, Dervaux et al. 2001).  Therefore, substance abuse in schizophrenics 
complicates the proper medication of these patients (Siris et al. 1998).   
Two hypotheses have been proposed to explain the increased rate of substance 
abuse in schizophrenics.  The first hypothesis suggests that schizophrenic patients 
abuse psychostimulant drugs in an attempt to alleviate aspects or symptoms of the 
disease (Akerele and Levin 2002, Gregg et al. 2007).  Studies have suggested that 
nicotine use may help alleviate sensory gating abnormalities and attentional deficits 
produced by schizophrenia (Le Duc and Mittleman 1995, Adler et al. 1998).    The 
second hypothesis focuses on the use of drugs to relieve negative side effects of the 
neuroleptic treatment of the disease.  Antipsychotic medications have been used in 
schizophrenia treatment since the early 1950s.  While these medications are helpful in 
allaying positive symptoms, antipsychotic treatment can also lead to disabling extra-
pyramidal motor symptoms such as parkinsonianism, dystonia, and dyskinesia.  Studies 
have attempted to address whether the use of psychostimulants in schizophrenic 
patients exacerbates extrapyramidal symptoms or is sought to alleviate those symptoms 
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(Dixon et al. 1991, Gao et al. 2008, Potvin et al. 2009).  Results have shown that 
patients with a dual diagnosis of schizophrenia and substance abuse exhibit worse 
extra-pyramidal symptoms than either disorder singly (Duke et al. 1994, Bailey et al. 
1998, Potvin et al. 2009). Clinical studies have not been able to determine the order of 
occurrence in the relationship between substance abuse in schizophrenics and 
extrapyramidal symptoms.  Confounding factors include a varied dosage of 
antipsychotics by individual, a variety of abused drugs often within a single subject, and 
the potential symptoms of psychostimulant withdrawal that may mimic some of the 
extrapyramidal symptoms.  
Another mechanism of studying the relationship between substance abuse and 
schizophrenia is the self-report.  Within the self-reporting literature, several reasons for 
use have been examined:  intoxication effects, social reasons, dysphoria relief, and 
alleviation of psychotic symptoms and to mitigate extrapyramidal symptoms.  Between 
35% and 95% of subjects reported using drugs or alcohol for the intoxicating effects 
(Dixon et al. 1991, Addington and Duchak 1997, Baker et al. 2002).  Between 8% and 
81% of schizophrenic patients cited social reasons as the cause for their drug use (Test 
et al. 1989, Dixon et al. 1991, Warner et al. 1994).  Up to 86% reported using drug or 
alcohol to relieve dysphoria (Test et al. 1989, Dixon et al. 1991, Warner et al. 1994).  In 
using drugs or alcohol to alleviate or cope with psychotic symptoms, results indicated 
that up to 42% of subjects responded affirmatively (Addington and Duchak 1997, Dixon 
et al. 1991, Test et al. 1898).  Between 0 and 48% reported using alcohol or drugs to 
alleviate negative side effects of medication (Test et al. 1989, Dixon et al. 1991, Warner 
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et al. 1994, Gregg et al. 2007).  Overall, there is no clear understanding of the full 
relationship of the dual diagnosis of schizophrenia and substance abuse.       
Dopaminergic Mechanisms of Amphetamine 
  Amphetamine is an indirect dopamine agonist known to increase extracellular 
dopamine in the striatum and nucleus accumbens (Wise 1996).  Amphetamine induces 
increases in dopamine overflow and prevents dopamine reuptake through inhibition of 
the dopamine transporter.  In addition to inhibiting dopamine reuptake, amphetamine 
causes the release of dopamine from the presynaptic terminals (Seiden et al. 1993).  
Amphetamine-induced dopamine release occurs by two mechanisms:  calcium-
dependent vesicular release and impulse-dependent or transporter-mediated release.  
Impulse-dependent release is independent and has little calcium dependence that is 
why often amphetamine is stated to increase dopamine overflow as compared to 
dopamine release (Hurd and Ungerstedt 1989, Pierce and Kalivas 1997).  
 Amphetamine can cross the plasma membrane via lipophilic diffusion as well as 
being a substrate for the dopamine transporter (DAT) (Zaczek et al. 1991a, 1991b).  
Once inside the neuron amphetamine (AMPH) displaces dopamine from the vesicles 
into the cytoplasm (Sulzer and Rayport 1990).  From the cytoplasm, DA can be 
released into the extracellular space by the dopamine transporter (Floor and Meng 
1996).  Studies have shown that both the depletion of dopamine from secretory vesicles 
and the reversal of DAT-mediated transport are necessary for the effect of 
amphetamine on overflow in dopaminergic neurons (Jones et al. 1998). 
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Behavioral Sensitization 
One common behavioral test to analyze the effects of amphetamine on 
behavioral activation is behavioral locomotor sensitization. Behavioral sensitization is 
the progressive and long-lasting augmentation of certain behaviors following repetitive 
stimulant drug treatment (Segal and Mandell 1974, Kalivas and Stewart 1991, Robinson 
and Berridge 1993).  Sensitized behaviors may occur with a shorter latency, higher 
intensity, or at a lower dose following repeated treatment with stimulant drugs including 
amphetamine or cocaine (Segal et al. 1980).  Behavioral sensitization is a two-step 
process, development and expression.  The development or initiation of amphetamine 
sensitization involves dopamine D1 and glutamate receptor activation within the ventral 
tegmentum and substantia nigra (Kalivas and Alesdatter 1993, Wolf et al. 1995, Bijou et 
al. 1996).  Expression is defined as the neuronal alteration arising from the initiating 
process that mediates the augmented behavioral response and that is mediated by the 
nucleus accumbens (Wolf 1998). Alterations include an increase in the non-NMDA 
glutamate AMPA receptor surface expression resulting from dopaminergic modulation in 
the nucleus accumbens following psychostimulant sensitization (Pierce 1996, Boudreau 
and Wolf 2005).  Measurements of locomotor activity including vertical, horizontal and 
rotational are typically used in experiments analyzing behavioral sensitization.  
Behavioral changes resulting from addictive drugs resemble behavioral 
responses elicited by natural reward, though the reward of addictive drugs has the 
power to supplant all other goals, making the drug reward a higher priority to the 
organism than all other rewards including food.  The rewarding properties of addictive 
drugs putatively require an increased dopaminergic release from midbrain ventral 
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tegmental area neurons onto nerves in the nucleus accumbens (Wise and Bozarth 
1987, Koob and Bloom 1988, Di Chiara 1998).  Ventral tegmental area dopamine 
projections to other forebrain areas such as the prefrontal cortex and the amygdala also 
play a role in shaping drug-taking behaviors (Everett et al. 1999).  Structural similarities 
in the nucleus accumbens shell and amygdala have led some to postulate the nucleus 
accumbens shell to be an extension of the amygdala, the region of the brain thought to 
be responsible for emotional and rewarding behaviors (Everritt et al. 1991, Meredith et 
al. 2002).  Despite the varying targets and chemical composition of the various classes 
of addictive drugs, they all cause an increase in synaptic dopamine within the nucleus 
accumbens. In order for addictive drugs to produce reward, they must utilize dopamine 
in a similar manner (Kelley and Berridge 2002).  It has been hypothesized that addictive 
drugs have competitive advantages over natural stimuli by producing far greater levels 
of dopamine release resulting in prolonged stimulation (Kelley and Berridge 2002).  
Modeling Substance Abuse in Animals 
Psychostimulants possess the ability to stimulate DA transmission in the nucleus 
accumbens (Di Chiara 2002).  Studies using amphetamine have shown that the 
dopamine system is critically important for development and expression of behavioral 
sensitization (Kalivas et al. 1993a, 1993b).  Acute or repeated amphetamine exposure 
results in augmented dopamine overflow in the striatum and nucleus accumbens (NAcc) 
in vivo (Wilkinson et al. 1993) and in vitro (Castandeda et al. 1988).  Local 
administration of amphetamine in the NAcc in animals previously sensitized to 
amphetamine also produces increased DA overflow in NAcc and striatum (Pierce and 
Kalivas 1996).  
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Dopamine System 
Dopamine is estimated to constitute up to 80% of the total catecholamine content 
in the brain, but the total number of dopaminergic cells is relatively small (Lindvall et al. 
1984, Williams and Goldman-Rakic 1998).  Three major divisions of dopaminergic 
pathways innervate the forebrain and basal ganglia (Bjorklund and Lindvall 1984, Lewis 
et al. 1998, Tzchentke 2001).  These cell groups are designated as A8, A9, and A10 
and generally corresponds to the DA cells of the substantia nigra (A9), ventral 
tegmental area (A10), and the retrorubral area (A8) (Porrino and Goldman-Rakic 1982, 
Williams and Goldman-Rakic 1998).  Dopaminergic neurons are functionally involved in 
higher motor execution, goal-directed behaviors including motivation, reward learning, 
prediction, and working memory (Egan and Weinberger 1997, Lewis et al. 1998).  
Impairment of these neurons results in neurological and psychiatric disorders 
(Goldman-Rakic 1998).   
Ascending dopaminergic fibers innervate a large number of subcortical and 
cortical structures including the neocortex.  Structures of the basal ganglia, particularly 
the striatum, receive the most dense dopaminergic input (Boyson et al. 1986).  Within 
the neocortex, sensory areas are sparsely innervated while cortical areas such as the 
primary motor cortex, prefrontal cortex, and anterior cingulate cortex are more densely 
innervated by dopaminergic neurons (Berger and Gaspar 1994, Durstewitz et al. 1999).  
This innervation reflects the role of dopamine in motivation, reward, motor function, and 
executive function as compared to involvement in sensory systems.   
There are several major dopaminergic pathways.  The nigrostriatal system 
originates in the substantia nigra pars compacta, the ventral tegmental area, and the 
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retrorubral nucleus and projects to the caudate, putamen, globus pallidus, and nucleus 
accumbens. The nigrostriatal pathway is important in motor control (Feldman et al. 
1996).  The mesolimbic system contains the circuitry involved in reward and originates 
in the ventral tegmental area, substantia nigra, and retrorubral nucleus and projects to 
the septum, amygdala, hippocampus, nucleus of the diagonal band, anterior olfactory 
nucleus, nucleus accumbens, and olfactory tubercles (Fuxe 1985).  The mesocortical 
pathway originates in the ventral tegmental area, projects to the frontal cortex, and is 
essential to the normal cognitive function of the prefrontal cortex (Feldman et al. 1986).   
The majority of neurons in the NAcc are GABAergic and they project 
predominately to the ventral tegmental area (VTA) and the ventral pallidum, regions 
thought to be involved in the rewarding effects of most drugs of abuse (Self 2004).  The 
GABA system modulates both dopamine and glutamate transmission within the NAcc 
and its areas of projection.  Glutamatergic neurons converge on the same dendritic 
spines of medium-size spiny GABA neurons as dopaminergic afferents without making 
direct connections between the glutamatergic and dopaminergic projections (Segovia 
and Mora 2001).  Pulvirenti and colleagues (1991) suggest that glutamate from the 
NAcc modulates stimulation at the level of the NAcc by interacting with the integrated 
output of the region. 
Dopamine Receptors 
 All known dopamine receptors are G-protein coupled, slow acting metabotropic 
receptors that functionally modulate other receptor systems and/or ion channels 
(Missale et al. 1998).  Activation of these receptors, through intracellular cascades, 
modulates properties of synapses and postsynaptic neurons.  There are five dopamine 
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receptor subtypes belonging to two families:  the D1-like receptors and the D2-like 
receptors.  Functionally, these two types of receptors have opposing actions in the 
cellular cascade.  The D1-like receptors activate adenylyl cyclase resulting in an 
increase of cyclic adenosine monophosphate (cAMP).  The D2-like receptors inhibit 
adenylyl cyclase resulting in a decreased concentration of cAMP (Greengard et al. 
1999).  The D1-like receptor family contains the D1 and D5 dopamine receptors, while 
the D2-like receptor family contains the D2, D3, and D4 dopamine receptors.  
 The distribution of the D1 receptors has been mapped by in vitro autoradiography 
using several agonists and antagonists.  The greatest densities of D1 receptors are 
found in the caudate, putamen, NAcc, and olfactory tubercle.  Lower densities are found 
in the neocortex, thalamus, cerebellum, hippocampus, septum, and hypothalamus 
(Boyson et al. 1986, Dawson et al. 1986, Wamsley et al. 1992, Duffy et al. 2000).   
 Activation of D1 dopamine receptors is necessary for the induction of 
sensitization by amphetamine in the VTA (Vezina 1996).   Sensitization produced by 
amphetamine in the ventral tegmental area is blocked by systemic injection of the D1 
antagonist SCH23390 (Vezina 1996). Pre-amphetamine administration of selective 
dopamine D1 or D2 antagonists have been shown to block amphetamine sensitization, 
although the D1 receptor has been shown to play a more important role than the D2, 
although this has not been thoroughly investigated (Vezina and Stewart 1989; 1996).   
Dopamine D1 receptors have a higher affinity for dopamine than D2 receptors (Seeman 
and Van Tol 1994). Systemic pretreatment with the D1 receptor antagonist SCH23390 
inhibited the locomotor activating effects of repeated psychostimulant administration 
and prevented the development of sensitization (Hummel and Unterald 2002).   Results 
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have also shown location specificity in the role of D1 receptors in sensitization.  It 
appears that noncortical D1 receptors are more important than cortical D1 receptors in 
the development of sensitization, intracortical administration of D1 antagonist failed to 
significantly affect psychostimulant induced locomotor activity or stereotypy, whereas 
D1 antagonist treatment within the ventral tegmental area has been shown to block 
sensitization (Beyer and Steketee 2002; Vezina 1996).   
 Dopamine D2 receptors are most densely located in the caudate, putamen, 
nucleus accumbens, olfactory tubercle, substantia nigra pars compacta, and the 
glomular layer of the olfactory bulbs with less dense populations in the central nucleus 
of the amygdala, lateral septum, superior colliculus, molecular layer of the 
hippocampus, and the entorhinal cortex (Boyson et al. 1986, Pinto and Sesack 2008).   
 Amphetamine induced sensitization may involve the D2 receptor both 
presynaptically at the autoreceptor, a receptor located on the presynaptic neuron 
terminal that serves as a part of a feedback loop in signal transduction, and at 
postsynaptic D2 receptors.  Daily amphetamine treatment has been shown to produce a 
subsensitization of dopamine D2 autoreceptors in the ventral tegmental area (Seutin et 
al. 1991, Wolf et al. 1993, Muscat et al. 1996). The subsensitization of D2 autoreceptors 
occurs in conjunction with an increased activity of A10 dopaminergic neurons in the 
ventral tegmental area (Pierce et al. 1995).    The increased activity in A10 neurons may 
result in priming of postsynaptic dopamine neurons (Ackerman and White 1992, Henry 
et al. 2000, Hopf et al. 2007).  In response to amphetamine treatment, the postsynaptic 
signal transduction is linearly correlated to extracellular dopamine concentration.  It has 
been suggested that at lower dopamine concentrations presynaptic binding may be 
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dominate to postsynaptic binding (Kuczenski and Segal 1989, Ren et al. 2009). 
Systemic administration of selective D2 antagonist (Vezina, 1989) has been shown to 
not affect amphetamine sensitization, and a less selective D2-like antagonist, 
eticlopride, that was also used in this study, has been infused into the ventral tegmental 
area and also shown to block amphetamine sensitization. However, there are no data 
on the systemic effects of eticlopride on amphetamine sensitization or its effects on 
dopamine overflow.  
 An important issue of the effects of neonatal quinpirole is the pre- and post-
synaptic effects of this drug treatment. Quinpirole is a dopamine D2/D3 agonist and D2 
as well as D3 receptor are located both pre- and post-synaptically. Blockade of 
postsynaptic receptors is generally considered to be the primary effect of neuroleptic 
administration and will result in a reduction of dopaminergic transmission.  For some 
dopaminergic neurons, this immediate effect is opposed by compensatory feedback 
mechanisms (Galloway 1990).  The blockade of presynaptic autoreceptors by 
neuroleptics results in an increased synthesis and release of dopamine from the 
dopaminergic terminal, thereby overcoming the blockade of dopamine receptors 
produced by the antagonist.  There are also long-loop neuronal feedback pathways that 
can be involved.  For example, during periods of enhanced postsynaptic dopamine 
receptor stimulation, these loops exert negative feedback effects on dopamine cell 
firing, whereas the blockade of postsynaptic receptors would produce a compensatory 
increase in dopamine cell firing (Benkert et al. 1992).  Within the mesolimbic system, 
data have shown that either the D1 agonist SKF 38393 or the D2 agonist quinpirole can 
increase extracellular dopamine levels in the nucleus accumbens in a dose-dependent 
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fashion without affecting dopamine levels in the ventral tegmental area (Rahman and 
McBride 2001).  Further, coadministration of SKF 38393 and quinpirole produce a 
concomitant reduction in the extracellular levels of dopamine in the nucleus accumbens 
as well as in the ventral tegmental area.  Blockade of either the D1 or D2 receptor was 
sufficient to reverse the effect of the coinfusion of agonists.  These results suggest that 
the activation of dopamine D1 or D2-like receptors are independently able to regulate 
local terminal dopamine release in the nucleus accumbens, but stimulation of both 
subtypes is required for activation of the negative feedback pathway to the ventral 
tegmental area (Rahman and McBride 2001). 
Sex Differences 
Studies of sex differences in schizophrenia have concluded that women tend to 
have a less intrusive course of illness including less hospitalizations and better social 
functioning than men (Mueser and McGurk 2004).  Studies have suggested that the 
later onset of schizophrenia in women is resultant of the effects of estrogen on D2 
receptors in the central nervous system (CNS). Studies have shown that estrogen 
treatment reduced the affinity of sulpiride to the D2 receptor, leading to the conclusion 
that estrogen treatment reduced the sensitivity of D2 receptors (Häfner et al. 1991a).  
Studies have also revealed an elevated vulnerability threshold to schizophrenia in 
women that persists until menopause, implicating the modulatory role of estrogen on the 
dopamine system (Häfner et al. 1998).  In female schizophrenic patients, a correlation 
was found that the higher the estradiol level, the more 'normal functioning' the behavior 
was judged to be (Reicher-Rössler et al. 1994).  Additionally, it has been suggested that 
estrogen might act on NMDA receptors as well, both in the menstrual cycles and over a 
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longer period of time.  This effect could contribute to the protective effect of estrogen in 
schizophrenia given the implications of the involvement of glutamate within the disease 
(Woolley and McEwen 1994). 
Sex Hormones and Psychostimulant Abuse 
Previous studies have indicated gender differences in the neurobiological 
response to psychostimulants and in behavioral sensitization (Becker 1999, Bowman et 
al. 1999).  Sex differences are present for all phases of drug abuse:  initiation, 
escalation of use, progression to addiction, withdrawal, and relapse (Haaren and Meyer 
1991, Van Etten et al. 1999, Lynch and Carroll 2002, Carroll et al. 2004).  While the 
rates of drug abuse are currently lower in women than men, once addicted to a drug, 
women show more difficulty in cessation of use than men (Lynch and Carroll 2002, 
Breese et al. 2005).  In women, the subjective effects of psychostimulants, particularly 
d-amphetamine, vary across the menstrual cycle.  Subjective positive effects including 
euphoria, increased energy, and intellectual efficiency were reported when estradiol 
levels are higher than progesterone levels during the follicular phase (Becker and Hu 
2008).  Administration of estradiol during the follicular phase further increases the 
subjective effects of d-amphetamine (Justice and De Wit 2000).  
The acute behavioral response to psychomotor stimulants in rodents reflects 
both the sex difference (including locomotor response, self-administration, and drug 
sensitivity) and the modulatory role of gonadal hormones in males and females (Becker 
and Beer 1986, Van Hatesveldt et al. 1989, Basser et al. 2000).   Behavioral 
sensitization can also be differentially affected by gonadal steroid hormones. For 
example, females exhibit more robust sensitization than do intact males (Robinson et al. 
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1981, Robinson et al. 1982, Camp and Robinson 1988, Forgie and Stewart 1994). 
Following ovariectomy of female rats, the expression of sensitization to AMPH is 
attenuated or completely suppressed (Robinson et al. 1982, Sicar and Kim 1999).  
Estradiol treatment in ovariectomized rats enhances locomotor sensitization induced by 
AMPH or cocaine (Peris et al. 1991; Forgie and Stewart 1994).  Studies have shown 
that female rats exhibit increased locomotor response to amphetamine treatment versus 
male rats (Becker 1999, Melnick and Dow-Edwards 2001).  Female rats also show 
greater and more prolonged stereotyped behavior following amphetamine treatment and 
more amphetamine induced rotational behavior than males (Beatty and Holzer 1978, 
Robinson et al. 1980).  
There are no sex differences in the number or binding characteristics of striatal 
D2 DA receptors in adult rats (Hruska and Dilbergeld 1980, Levesque and Di Paolo 
1988, Teicher et al. 2003).    Striatal D2 receptor density increases at the onset of 
puberty but is decreased significantly by adulthood in males.  Periadolescent females 
show less overproduction and pruning of striatal D1 and D2 receptors (Andersen and 
Teicher 2000).  There are sex differences in basal and amphetamine (AMPH)-
stimulated striatal DA release in the absence of gonadal hormones.  Results from in 
vivo microdialysis in freely moving rats show that the basal extracellular concentration of 
DA is twice as high in the striatum of castrated males as in ovariectomized females 
(Xiao and Becker 1994).  Enduring differences in D1 receptor density may play a role in 
the greater incidence of substance abuse in males given the implied role of the D1 
system in the development of addiction (Naldonado et al. 1993). 
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In cultured striatal neurons from embryonic mice, estradiol administration induces 
changes in adenylate cyclase activity that are stimulated by D1 and D2 dopamine 
receptor agonists by modifying the G-protein coupling process (Maus et al. 1989a, 
Maus et al. 1989b).  Administration of physiological concentrations of estradiol to striatal 
slices directly stimulated DA release in vitro (Becker 1990).  Estradiol works directly on 
the striatum to induce changes in DA release and DA receptor activity.  Further studies 
have indicated that the effect of estradiol on striatal DA release may be mediated 
indirectly by the effect of estradiol on GABAergic striatal neurons (Becker and Hu 2008).   
Estrus Cycle and Psychostimulants 
It has been hypothesized that dopamine function in females may be influenced 
significantly by the fluctuation of ovarian hormones throughout the estrus cycle (Becker 
1990).  The estrus cycle of the female rat has three stages:  proestrus, diestrus, and 
estrus.  This cycle typically recurs every 4 days (Marcondes et al. 2002).  Ovarian 
hormone fluctuations induce variation in behavioral and neurochemical responses to 
psychostimulant drugs.  Behavioral estrus occurs simultaneous to vaginal estrus and 
therefore an increased estrogen level is present during this time as well a behavioral 
estrus.  During behavioral estrus in female rats, amphetamine-induced dopamine 
release in the striatum and amphetamine behaviors are greater than on others days of 
the estrus cycle (Becker et al. 1980, Becker et al. 1982, Becker et al. 1989, Becker et al. 
2001).  Studies have shown that a greater behavioral response is elicited from female 
rats with stimulation of the striatal dopamine system during behavioral estrus as 
compared to diestrus (Becker et al. 1982, Kalivas and Stewart 1991). 
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Goals of This Study 
Research on psychosis has indicated a high comorbidity of substance abuse and 
psychosis.  In those cases with comorbid substance abuse and schizophrenia the drugs 
of choice are often psychostimulants and more specifically amphetamine or nicotine.  
Therefore, further investigations into amphetamine sensitization in a putative model of 
psychosis may offer insight of the mechanisms involved in comorbidity.   
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CHAPTER 2  
METHODS 
 This study uses neonatal quinpirole treatments from postnatal days 1-11 to 
produce life-long changes consistent with some aspects of schizophrenia.  Past studies 
by Kostrzewa and colleagues (Nowak et al. 2001) have shown that neonatal quinpirole 
treatment results in long-term increases in sensitivity of D2-like receptors. Adult animals 
were then treated with either SCH23390 (a D1 receptor antagonist) or eticlopride (a D2-
like receptor antagonist) in an amphetamine behavioral sensitization design, with 
animals given amphetamine or saline every other day over a 14-day period for a total of 
7 drug treatments. Approximately 15 mins before each amphetamine or saline 
treatment, a D1 antagonist (SCH23390), D2 antagonist (eticlopride), or saline will be 
given to produce blockade of D1 and D2 receptors.  
One day after sensitization is complete, a guide cannula will be surgically 
implanted. Six to 8 days later, an amphetamine or saline challenge will be given. 
However, a microdialysis probe will be placed into the nucleus accumbens core during 
this challenge. On the challenge, animals will be given the same antagonist and 
adulthood drug treatment that they received during behavioral testing on the challenge.  
 The goals of this study are to determine the role of the dopamine D1 and D2 
receptors in the amphetamine-induced sensitization of rats neonatally treated with 
quinpirole.  Additionally, the study investigated potential sex effects of treatments on 
females versus males. It is hypothesized based on past findings (Vezina 1989) that a 
dopamine D1 antagonist would block amphetamine behavioral sensitization and no 
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increase in locomotor activity would be seen following amphetamine sensitization. In 
terms of the effects on dopamine overflow, it is hypothesized that D1 antagonism will 
completely block the effects of amphetamine on dopamine overflow based on past 
findings (Vezina 1996).  
Additionally, a D2/D3 antagonist was hypothesized to reduce sensitization versus 
saline treated control animals, although not to the level of animals given a D1 
antagonist. The D2 receptor has been shown to not play a role in amphetamine 
sensitization (Vezina 1996, others), but antagonism of the D3 receptor has been shown 
to block amphetamine sensitization (Richtand et al. 2003). Based on this finding, it is 
hypothesized that antagonist treatment wit the D2/D3 antagonist eticlopride will reduce 
sensitization although not to the levels of D1 antagonism. It is hypothesized that pre-
treatment with eticlopride will actually potentiate the effects of amphetamine on 
dopamine overflow based on the fact that eticlopride will block the D2 and D3 
autoreceptors presynaptically, that should enhance dopamine release at the synapse.  
Information in Figure 1 describes the treatment groups for this study, beginning with 
neonatal treatment and including antagonist treatment as well as adult drug treatment.  
Neonatal treatments were given once daily P1-11.  The antagonist treatments were 
administered approximately 15 minutes prior to the adult drug treatment.  Following 
adult drug treatment (10 minutes after administration), animals were placed in locomotor 
arenas for testing.  
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Figure 1  Diagram of drug treatments throughout the study.  White boxes denote treatments during neonatal periods, prior 
to weaning.  Gray boxes denote treatments involved in behavioral sensitization and microdialysis.  AMPH denotes 
treatment with d-amphetamine.  
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Subjects and Housing of Animals 
A total of 10 untimed pregnant female Sprague Dawley rats were ordered from 
Harlan, Inc. (Indianapolis, IN).  Once animals arrived, they were housed separately for 7 
days. Throughout the experiment animals were kept in an Association for Assessment 
and Accreditation of Laboratory Animal Care (AAALAC) accredited colony with a 12h 
light/dark cycle.  All behavioral testing and neurochemical sampling occurred during the 
light cycle. After an initial quarantine period, the pregnant rats were housed singly until 
the pups were born, that was counted as postnatal day (P)0.  Following birth, pups were 
housed with the female dams until P21.  On P22, rats were weaned and housed in 
groups according to their neonatal treatments throughout adolescence and during 
amphetamine sensitization behavioral testing.  Upon surgical implantation of the guide 
cannula, rats were singly housed for the remaining duration of the experiment. 
Neonatal Drug Treatment 
Animals were injected with either quinpirole (1 mg/kg) or saline at a total volume 
of 1% of their body weight during treatment, P1-11.  Following injections, the needle 
was left in place for approximately 5 seconds to avoid loss of drug as a result of 
capillary action resulting from needle removal.       
Drugs  
 All drug were administered through intraperitoneal (ip) injection, with the 
exception of postoperative ketoprofen that was given by intramuscular injection.  For 
neonatal drug treatment and the yawning test quinpirole HCl (Sigma-Aldrich, St. Louis, 
MO) was administered. A dose of 1.0 mg/kg of the D2/D3 agonist quinpirole (or saline) 
was injected intraperitoneally (ip) for neonatal treatment.  Previous studies have shown 
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this dose to be sufficient to produce an increase in dopamine D2 receptor sensitivity that 
will persist throughout the animal‟s lifetime (Kostrzewa et al. 1991, 1993, 1995).  During 
behavioral sensitization a dose of 1.0 mg/kg d-amphetamine injected ip (Sigma-Aldrich, 
St. Louis, MO) was administered every other day over a 14-day period to adult rats.  
Previous data indicated that a dose of 1.0 mg/kg amphetamine was sufficient to 
produce increased dopaminergic overflow in animals neonatally treated with quinpirole.  
Additionally, this dose of amphetamine has been shown to produce behavioral 
sensitization (Hooks et al. 1992, Cadoni et al. 2002, Vanderschuren et al. 2003).  For 
receptor antagonism, the D1 antagonist SCH 23390 (7-Chloro-8-hydroxy-3-methyl-1-
phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride) was administered at a dose 
of 0.1 mg/kg (ip injection), that has been shown to be effective at blocking sensitization 
to a dose of 1.0 mg/kg amphetamine (Vezina 1996).  The D1 antagonist, SCH 23390 
has a >1000 times higher affinity at the D1 receptor as compared to the D2 receptor 
(Seeman and Grigoriadis, 1987). For D2 antagonism, a dose of 1.0 mg/kg eticlopride 
was administered.  This eticlopride dose has been shown to block behavioral changes 
produced by 1.0 mg/kg doses of amphetamine (Vezina 1996).  Eticlopride has >2.5x106  
more affinity at the D2 receptor than the D1 receptor (Vezina 1996).  The vehicle for all 
drug preparations was a 0.9% saline solution. 
Yawning Behavior 
 At approximately P60, a time point equating to young adulthood in the rat, 
animals were tested for yawning behavior.  Yawning has been shown to be a dopamine 
D2-like receptor mediated event.  Studies have shown that this behavior may be 
mediated either by D2 (Cooper et al. 1989) or the D3 receptor subtype (Collins et al. 
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2005), although both of these receptors are members of the D2 receptor family.  Prior to 
testing, all animals were administered quinpirole (100 μg/kg) and placed in an inverted 
cage without bedding.  Bedding can result in chewing behavior that interferes with the 
observance and expression of the yawning behavior.  Previous work indicated this dose 
of quinpirole resulted in the most robust yawning response within a 1-hr period for each 
subject (Nowak et al. 2001).  An observer blind to treatment condition observed the 
behavior for the period of 1 hour.  
Habituation to the Locomotor Arena 
 Beginning at approximately 61 days of age, animals began habituation to the 
locomotor arena.  For habituation, animals were placed in the locomotor arena for 10 
minutes every 2nd day for 1 week.  Immediately before each habituation session rats 
were administered an ip injection of saline. Animals were injected with saline to control 
for any locomotor effect that may exist as a result of the stress produced by the 
injection.   
Behavioral Sensitization 
 Behavioral sensitization began approximately 2 days after the last habituation 
session.  For each sensitization trial, approximately 10 minutes before injection of saline 
or amphetamine, rats were injected with the D1 receptor antagonist SCH23390, the D2 
receptor antagonist eticlopride, or saline. Ten minutes before placement in the arena, 
rats were administered with amphetamine (1.0 mg/kg) or saline based on group 
assignment.  Once in the arena, horizontal activity was monitored for 10 minutes using 
an automated behavioral scanning system (AnyMaze, Stoelting Co, Dale Wood, IL ).  
For horizontal activity measurements, the AnyMaze software digitally superimposes a 5 
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x 5 cm grid on the floor of the arena.  Each time an animal crosses a line on the grid it is 
counted as a horizontal activity count.  The total number of activity counts for each 10-
min trial provided a quantification of the total horizontal activity.   
 As an additional behavioral measure turning behavior, both clockwise and 
counterclockwise was analyzed.  Previous work has shown that rats demonstrate a 
drug-induced turning preference that is consistent in direction and correlated with the 
magnitude of turning when rats are retested with the same dose of the same drug 
(Becker et al. 1982, Glick et al. 1983).  Turning behavior has been shown to be an 
effective measure of striatal function lending some additional information to the current 
study design (Robinson 1984).   
Surgical Procedure for Implantation of Guide Cannula 
 On the day following the completion of amphetamine behavioral sensitization, a 
guide cannula (Bioanalytical Systems, Lafayette, IN) was surgically implanted, aimed at 
the nucleus accumbens core.  Animals were first injected ip with a mixture of ketamine 
and xylazine for surgery to allow placement of the animal into the stereotaxic frame.  
However, the ratio of the ketamine/xylazine mixture was different based on the sex of 
the animal. Males were injected with a mixture of 60 mg/kg ketamine:8 mg/kg xylazine 
and females were injected with a mixture of 50 mg/kg ketamine: 10 mg/kg xylazine.  
These different doses helped to account for potential differences in metabolism of the 
anesthetic agents between male and female rats and to maintain proper levels of 
anesthesia during surgery (Zambricki and Dalecy, 2004).  After the animal was 
anesthetized, the head  was shaved and placed into the ear bars of a Kopf (Kopf 
Instruments, Inc., Tunjunga, CA) stereotaxic frame, and the nose of the animal was 
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inserted into a Kopf stereotaxic mask (Model 906, Kopf Instruments, Inc., Tunjunga, 
CA).  The mask was connected to an anesthesia machine (JD Medical VT-100, 
Phoenix, AZ) that delivered an isoflurane/O2 mixture (1-1.5%) at a rate of 2 L/min. An 
incision was made on the midline of the scalp and the covering connective tissue 
removed from the skull.  A small hole was drilled through the skull at the following 
coordinates relative to Bregma:  Anterior/Posterior = +1.0 mm, Medial/Lateral = +/-1.2 
mm. The guide cannula was inserted through this opening to a dorsal level of 6 mm 
below bregma. These coordinates, taken from the stereotaxic atlas of Paxinos and 
Watson (1986) correspond to the dorsal location of the nucleus accumbens core.  Three 
other small burr holes were drilled for the anchor screws and screws were attached to 
the skull. Dental acrylic was mixed (1.0 g powder, 2.0 mL methyl methacrylate) and 
poured onto the skull and around the anchor screws to secure the cannula in place.  
Once the acrylic was dry, the incision was sutured closed and wound clips were placed 
over the sutures.  After the wound was closed, the animal was removed from the 
stereotaxic frame and placed in an empty polycarbonate cage on a heating pad.  
Additionally, to ease postoperative discomfort, all animals were injected intramuscular 
with ketoprofen (5 mg/kg) and 10 cc of saline to replenish fluids lost during the surgical 
procedure.  The animals were allowed to recover and returned to their home cage once 
ambulatory.  Following microdialysis, the brains were analyzed by dissection for proper 
probe placement.  Animals with incorrect probe placement were not included in the 
results. 
 
 
 45 
 
Estrus Cycle 
 On each day of testing as well as on the day of microdialysis, the state of estrus 
cycle of female rats was verified.  A sample of cells was taken from the animal's vaginal 
lumen using a saline-moistened cotton swab.  The sample was placed on a slide and 
analyzed under a microscope (Olympus microscope BH series).  The stage of the 
estrus cycle was used as a variable in initial analysis of locomotor activity and dopamine 
overflow to determine if the stage of the estrus cycle impacted locomotor activity and/or 
dopamine overflow in the nucleus accumbens.   
Microdialysis and Amphetamine Challenge 
 Seven-10 days after amphetamine sensitization was complete, a microdialysis 
pin probe (Bioanaltyical, Lafayette, IN) was implanted through the guide cannula with 
2.0 mm of active membrane exposed.  Prior to insertion of the probe, it was washed 
with artificial CSF for a period of 1 hour.  Once the animal was attached to the probe, 
artificial CSF [145 mM sodium chloride, 2.7 mM potassium chloride, 1.0 mM magnesium 
chloride, 1.2 mM calcium chloride, 2.0 mM sodium phosphate at a pH of 7.4, Fisher 
Scientific] was perfused continuously at 2.0 μl/min through the dialysis probe for the 
duration of the procedure.  Baseline samples were collected at 20-min intervals for 2 
hours prior to drug administration.  Following the baseline samples, rats were injected ip 
with saline, SCH 23390, or eticlopride, matching the antagonist treatment during 
sensitization.  After the baseline period, d-amphetamine sulfate was injected using a 
cumulative dosing procedure similar to that used by Schad et al. (1996).  Over the next 
four 20 minute intervals, rats were given an injection of the following doses of d-
amphetamine in this order:  0.1 mg/kg, 0.4 mg/kg, 1.0 mg/kg, and 1.5 mg/kg.  This 
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application results in a cumulative dose of 3.0 mg/kg of amphetamine by the end of the 
drug administration.  Samples were collected every 20 min throughout drug treatment 
and 0.1 M perchloric acid was added to each vial to prevent catecholamine degradation.  
Samples were stored at -80 degrees C for later analysis. 
HPLC Analysis 
 In preparation for analysis, several concentrations of dopamine (DA), 3,4 
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and norepinephrine 
(NE) were prepared in order to construct a standard curve from that the concentrations 
of catecholamines could be calculated.   Before analysis, samples were thawed.  
Samples were injected into vials for analysis using an autosampler (ESA, Chelmsford, 
MA).  The autosampler injected 40 µl of each sample onto the detection column 
allowing the sample to separate into its constituents that cleared the column at specific 
retention times.  The area of each target peak was compared to the standard curve to 
calculate the concentration for each compound.  The baseline concentrations of DA, 
DOPAC, HVA, and NE were all calculated in picograms (pg) per 10 µl.  For 
microdialysis of all compounds following drug treatment, the percentage of baseline was 
calculated based on the concentration of the target compound at each time point.   
Statistical Analysis 
 Analysis of variance (ANOVA) was the primary statistical test with a Fischer‟s 
post–hoc test used for statistical analysis of all significant interactions.  The statistical 
significance was set at p<0.05 for all analyses. In the research design, there were four 
independent variables:  neonatal drug treatment (between subjects, 2 levels: quinpirole 
or saline); antagonist treatment (between subjects, 3 levels: SCH23390, eticlopride, or 
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saline) adulthood drug treatment (between subjects, 2 levels: amphetamine or saline) 
and sex (between subjects, 2 levels: male or female).  Regarding microdialysis, the time 
points were used as a repeated measure for the ANOVA analysis with regard to drug 
treatment (neonatal, antagonist, and adult drug treatment) and expressed as a 
percentage of baseline levels.  Baseline levels were calculated by averaging the 
dopamine overflow concentrations of the three samples from the last hour of baseline 
collection.  The drug treatment samples were then calculated as a percentage of the 
baseline with each animal calculated independently.  For this analysis, a 2 x 2 x  3 x 9 
four-way ANOVA was initially used, with sex dropped as a variable when no sex 
differences were found.  Table 1 outlines the subject numbers and treatments for the 
duration of the study.   
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Table 1  Numbers and sexes of subjects and the treatment groups for treatment 
throughout the study design.  Neonatal treatments were given P1-11.  The antagonist 
treatments were administered during adulthood on behavioral testing days and on the 
day of microdialysis. 
Subjects Neonatal treatment Antagonist treatment Adult drug treatment 
8 Males, 8 Females Saline Saline Saline 
8 Males, 8 Females Saline Saline Amphetamine 
8 Males, 8 Females Quinpirole Saline Saline 
8 Males, 8 Females Quinpirole Saline Amphetamine 
8 Males, 8 Females Saline SCH23390 Saline 
8 Males, 8 Females Saline SCH23390 Amphetamine 
8 Males, 8 Females Quinpirole SCH23390 Saline 
8 Males, 8 Females Quinpirole SCH23390 Amphetamine 
8 Males, 8 Females Saline Eticlopride Saline 
8 Males, 8 Females Saline Eticlopride Amphetamine 
8 Males, 8 Females Quinpirole Eticlopride Saline 
8 Males, 8 Females Quinpirole Eticlopride Amphetamine 
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CHAPTER 3 
RESULTS  
Amphetamine Sensitization 
Horizontal Activity 
A repeated measures five-way ANOVA was used as the primary statistical 
measure.  There were a total of five factors in the experimental design:  sex (2 levels: 
male, female), neonatal drug treatment (2 levels: quinpirole, saline), antagonist 
treatment (3 levels: saline, SCH23390, eticlopride), adult drug treatment (2 levels: 
amphetamine, saline), and day of testing (repeated measure: day 1, day 7).  Subjects 
were behaviorally tested for 7 days, but analysis included only days 1 and 7 to compare 
the beginning and end of drug treatment.  The analysis of the microdialysis experiments 
revealed no sex differences and data were consolidated over the sex variable. Across 
all behavioral analyses there were no significant effects of estrus cycle stage; therefore, 
data analyses were collapsed across that variable.  A 2 (sex) X 2 (neonatal drug 
treatment) x 2 (adulthood drug testing) x 2 (day of testing)  x 3 (antagonist treatment)  
five-way ANOVA revealed significant main effects for antagonist treatment, F(1,143) = 
121.21, p<0.001, adult drug treatment, F(1,143) = 35.19, p<0.001, and day of treatment, 
F(1, 143) = 4.90, p<0.029.  There were six significant two-way interactions: neonatal 
drug treatment x day of testing, F(1,143) = 4.867, p<0.029, antagonist treatment x day 
of testing, F(2, 143) = 10.65, p<0.001, adult drug treatment x day of testing, F(1, 143) = 
4.39, p<0.001, neonatal drug treatment x antagonist treatment, F(2, 143) = 6.70, 
p<0.002, neonatal drug treatment x adult drug treatment F(1, 143) = 12.63, p<0.001, 
and antagonist treatment x adult drug treatment, F(2, 143) = 15.96, p<0.001.  There 
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were also two significant three-way interactions of neonatal drug treatment x antagonist 
treatment x adult drug treatment, F(2, 143) = 3.10, p<0.048 and sex x neonatal 
treatment x antagonist F(2,143) = 2.844, p<0.043.  Table 2 indicates treatment codes 
for analysis.  
 
Table 2  Treatment codes and abbreviations for groups. 
Neonatal treatment Antagonist 
Treatment 
Adult Drug 
Treatment 
Group 
Abbreviation 
Saline Saline Saline SSS 
Saline Saline Amphetamine SSA 
Quinpirole Saline Saline QSS 
Quinpirole  Saline Amphetamine QSA 
Saline Eticlopride Saline SES 
Saline Eticlopride Amphetamine SEA 
Quinpirole Eticlopride Saline QES 
Quinpirole Eticlopride Amphetamine QEA 
Saline SCH23390 Saline S1S 
Saline SCH23390 Amphetamine S1A 
Quinpirole SCH23390 Saline Q1S 
Quinpirole  SCH23390 Amphetamine Q1A 
 
 Analysis of the significant three-way interaction of neonatal drug treatment x 
antagonist treatment x adult drug treatment revealed that Group QSA demonstrate 
higher levels of activity than all other groups across both days of analysis.  This finding 
demonstrates that neonatal quinpirole treatment produced a significant enhancement of 
the horizontal activity response to amphetamine, and this was blocked by either SCH 
23390 or eticlopride.  Analysis of the significant three-way interaction of sex x neonatal 
drug treatment x antagonist showed that SCH23390 and eticlopride were both effective 
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at blocking amphetamine sensitization in males, but in females only SCH 23390 was 
effective, as Group SSA and SEA were equivalent at days 1 and 7 and both of these 
groups were significantly higher than controls (Group SSS), figures 2 and 3. Therefore, 
it appears that males demonstrate an increased sensitivity to a D2-like antagonist as 
compared to females. Of course, this conclusion should be treated with some caution 
because only one dose of each antagonist was tested.  
Analysis of the significant two-way interactions revealed that neonatal quinpirole 
treatment produced a significant increase in horizontal activity on day 7 as compared to 
day 1. SCH 23390 produced a significant decrease in activity compared to controls on 
days 1 and 7, whereas eticlopride actually produced a significant increase in horizontal 
activity compared to controls at days 1 and 7. Amphetamine produced a significant 
increase in horizontal activity at day 7 as compared to day 1. SCH 23390 was more 
effective at blocking the effects of neonatal quinpirole treatment than eticlopride, likely 
due to eticlopride‟s blockade of inhibitory D2-like autoreceptors. Neonatal quinpirole 
treatment enhanced the locomotor activity response to amphetamine compared to 
animals given neonatal saline. Finally, SCH23390 was more effective at blocking the 
effects of amphetamine compared to eticlopride, as expected, and this is supported by 
past work (Vezina, 1996).  Analysis of the significant main effects revealed that  
SCH23390 reduced activity levels more effectively than eticlopride treatment and also 
prevented amphetamine-induced sensitization, supporting previous literature (Vezina 
1996). Finally analysis of the significant main effect of adulthood drug treatment 
revealed that d-amphetamine significantly increased horizontal locomotor activity across 
days of testing as compared to saline controls, as expected.  In sum, it appears that the 
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D1 antagonist SCH 23390 was effective at blocking amphetamine sensitization and 
producing locomotor hypoactivity, whereas the D2-like receptor antagonist eticlopride 
blocked amphetamine sensitization, but produced less locomotor hypoactivity in 
females as compared to males, and did not produce hypoactivity compared to controls. 
This was to be expected, as eticlopride blocks the inhibitory dopamine D2 autoreceptor 
and therefore increases dopaminergic activity, that would be expected to produce an 
increase in locomotor activity.  
A) SCH23390 - males 
* indicates a significant difference in the saline-saline-amphetamine group 
** indicates a significant difference from all other groups in the response of the 
quinpirole-saline-amphetamine group 
 
Figure 2 A) Horizontal activity of male subjects treated with SCH23390. 
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B) Eticlopride - males 
 
 
* indicates a significant difference in the saline-saline-amphetamine group 
** indicates a significant difference from all other groups in the response of the 
quinpirole-saline-amphetamine group 
 
Figure 2  B) Horizontal activity of male subjects treated with eticlopride.  The QSA group 
had significantly different activity levels than all other groups on both days 1 and 7.  
SSA animals showed significantly higher activity levels than saline-treated control 
animals.  SCH23390 was effective at lowering activity levels in all treatment constructs 
to below control levels.   Data are presented as means of groups +/- SEM. 
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A) SCH23390 - females 
 
* indicates a group with a significant difference from control 
** indicates a group with a significant difference from all other groups 
 
Figure 3 A) Horizontal activity of female subjects treated with SCH23390. 
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B) Eticlopride - females 
* indicates a group with a significant difference from control 
** indicates a group with a significant difference from all other groups 
Figure 3 B) Horizontal activity of female subjects treated with eticlopride. SSA animals 
demonstrated a significant increase in activity over control animals.  SCH23390 treated 
groups exhibited lower levels of horizontal activity compared to control animals.  The 
SES group showed significantly greater activity than control animals on both days 1 and 
7, with levels similar to the SSA group.  Data are presented as means of each group +/- 
SEM. 
 
 
 
 
 
 
 
 56 
 
Turning Behavior 
 Results are shown in figures 4 (males) and 5 (females).  For turning behavior, an 
initial analysis revealed no directional differences, so total (clockwise and 
counterclockwise) turns were summed and averaged for each group on days 1 and 7. 
Turning is presented as a function of neonatal drug treatment, antagonist drug 
treatment, adult drug treatment, and day of testing in Figure 3.    A 2 x 2 x 2 x 2 x 2 five-
way ANOVA revealed a significant main effect of antagonist drug treatment F(1,162) = 
98.81, p<0.001, day of treatment F(1,126) = 9.637, p<0.002 and adult drug treatment 
F(1,162) = 6.395, p<0.013, one significant three-way interaction of Day X Antagonist 
Treatment X Adult Drug Treatment F(1,162) = 3.802, p<0.025, one significant four-way 
interaction:  Day X Sex X Neonatal Treatment x Antagonist Treatment F(1,162) = 3.915, 
p<0.05, and a significant five-way interaction of Day of Treatment X Sex X Neonatal 
Treatment X Antagonist Treatment X Adult Drug Treatment F(1,162) = 4.242, p<0.041.  
Analysis of the significant five-way interaction demonstrated that females given neonatal 
quinpirole, saline as antagonist treatment and amphetamine as adult drug treatment 
demonstrated a significantly higher amount of turning behavior as compared to all other 
groups on the 1st day of treatment (day 1). Both SCH23390 and eticlopride blocked 
increases in turning behavior produced by amphetamine, and SCH23390 was more 
effective at blocking increases in turning behavior produced by amphetamine as 
compared to eticlopride, consistent with the horizontal activity results. Analysis of the 
significant four-way interaction again revealed that females given neonatal quinpirole 
treatment and saline as antagonist treatment demonstrated significantly higher amount 
of turning behavior on day 1. Post hoc analysis of the significant three-way interaction 
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revealed that animals given saline as antagonist treatment and amphetamine as adult 
drug treatment demonstrated significantly higher levels of turning behavior on day 7 
compared to all other groups.  The significant main effects revealed that SCH23390 
blocked the increase in turning behavior more so than eticlopride, although both 
significantly reduced turning behavior as compared to saline treated control subjects, 
and amphetamine significantly increased turning behavior.  It appears that D2 priming 
as is produced by neonatal quinpirole treatment enhanced amphetamine-induced 
turning behavior, but this effect was blocked by either D1 or D2 antagonism.                 
A) Males SCH23390 
 
 
* indicates a group with a significant difference from control 
** indicates a group with a significant difference from all other groups 
 
Figure 4 A) Turning behavior of male subjects treated with SCH23390.   
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B) Males Eticlopride 
 
* indicates a group with a significant difference from control 
** indicates a group with a significant difference from all other groups 
 
Figure 4 B) Turning behavior of male subjects treated with eticlopride. SSA animals 
demonstrated a significant increase in turning over control animals.  SCH23390 treated 
groups exhibited lower levels of horizontal activity compared to control animals.  The 
QSA group showed significantly greater activity than all other groups on both days 1 
and 7.  Data are presented as the mean of each group +/- SEM. 
 
* 
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A) Female SCH23390   
 
* indicates a group with a significant difference from control 
** indicates a group with a significant difference from all other groups 
 
Figure 5 A) Turning behavior of female subjects treated with SCH23390.   
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B) Female Eticlopride 
 
* indicates a group with a significant difference from control 
** indicates a group with a significant difference from all other groups 
 
Figure 5 B) Turning behavior of female subjects treated with eticlopride. SSA animals 
demonstrated a significant increase in turning over control animals on Day 7.  
SCH23390 treated groups exhibited lower levels of turning compared to control animals.  
The QSA group showed significantly greater activity than all other groups on both days 
1 and 7.  Data are presented as group means +/- SEM. 
 
Microdialysis 
 As with behavior, there were a total of five factors in the experimental design:  
sex (male, female), neonatal drug treatment (2 levels: quinpirole, saline), antagonist 
treatment (3 levels: saline, SCH23390, eticlopride), adult drug treatment (2 levels: 
amphetamine, saline), and time point after drug administration (repeated measure: time 
point after drug administration). Across all analyses regarding DA, DOPAC, HVA, and 
NE, there were no significant sex differences revealed and data were collapsed across 
that factor for analysis. Thus, a four-way repeated measures ANOVA was the primary 
 61 
 
statistical measure for analysis of dopamine levels in the nucleus accumbens core 
Additionally, initial analysis also revealed no significant effect of estrus cycle stage, so 
data were collapsed over that factor as well.  
 
Dopamine Overflow 
 Dopamine overflow in the nucleus accumbens core is presented as a function of 
adult drug treatment and antagonist drug treatment in figures 6 (SCH23390) and 7 
(eticlopride).  
A four-way repeated measures ANOVA revealed three significant main effects:  
time point F(8,84) = 2.46, p<0.012, antagonist drug treatment F(2,84) = 9.41, p<0.001 
and adult drug treatment F(1,84) = 6.24, p<0.014, as well as four significant two-way 
interactions:  neonatal drug treatment x antagonist drug treatment F(2,84) = 4.61, 
p<0.013, neonatal drug treatment x adult drug treatment F(1,84) = 4.58, p<0.04, 
antagonist drug treatment x adult drug treatment F(2,84) = 12.77, p<0.001, time point x 
antagonist drug treatment F(8,84) = 2.77, p<0.001 and one significant three-way 
interaction time point x antagonist drug treatment x adult drug treatment F(16,84) = 2.67 
p<0.001.  Post hoc analysis of the significant three-way interaction revealed that 
amphetamine produced a significant increase in dopamine overflow in animals given 
saline for antagonist drug treatment at the 20-180 min time points. Post hoc analyses of 
the significant two-way interactions revealed that neonatal quinpirole treatment coupled 
with saline treatment for the antagonist drug treatment significant increased dopamine 
overflow; neonatal quinpirole treatment enhanced dopamine overflow in animals treated 
with amphetamine; rats given saline during antagonist drug treatment coupled with 
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amphetamine for adult drug treatment demonstrated a significant increase in dopamine 
overflow, and saline during antagonist treatment produced a significant increase in 
dopamine overflow at time points 20-180 min after drug treatment. Amphetamine 
treatment resulted in a significant increase in dopamine overflow as expected.  Neonatal 
quinpirole treatment followed by adult d-amphetamine administration resulted in the 
greatest increase in dopamine overflow (Nowak et al. 2001, Cope et al. 2008).  Thus D2 
priming appears to poteniate the increase in dopamine overflow seen following adult 
amphetamine administration.  It appears that both SCH23390 and eticlopride can 
effectively attenuate the D2 priming effect that results in increased dopamine overflow in 
the nucleus accumbens.  This may be the result of a lack of D1/D2 synergism in the 
presence of antagonism of either the D1 or D2 receptor.   
 
 
Figure 6  Dopamine overflow in subjects treated with SCH23390. Group QSA exhibited 
significantly higher levels of dopamine in samples than all other groups. Group SSA 
also exhibited increased dopamine levels compared to antagonist treated subjects. A 
single * represents a significant difference from saline-treated control subjects (SSS).  ** 
represent a significant difference from all other groups.  Arrows indicate cumulative 
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dosing of amphetamine as the experiment progressed.   Values are means for each 
group +/- SEM. 
 
 
 
 
Figure 7 Dopamine overflow in subjects treated with eticlopride.  Eticlopride treated 
subjects demonstrated no significant difference in dopamine levels compared to control 
subjects.  A single * represents a significant difference from control subjects.   
** represent a significant difference from all other groups.  Arrows indicate cumulative 
dosing of amphetamine as the experiment progressed.  Values are means for each 
group +/- SEM. 
 
DOPAC Overflow 
 A four-way repeated measures ANOVA revealed two significant main effects:  
time point F(8,96) = 2.41, p<0.014, adult drug treatment F(1,96) = 5.75, p<0.018, and 
one significant three-way interaction neonatal drug treatment x antagonist drug 
treatment x adult drug treatment F(2,96) = 3.79, p<0.026.  Post-hoc analysis of the 
significant three-way interaction revealed that neonatal quinpirole treatment coupled 
with SCH-23390 and amphetamine treatment in adulthood produced a significant 
increase in DOPAC overflow, data represented in table 3.  Neonatal quinpirole 
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treatment resulted in an increase in DOPAC, and SCH 23390 was unable to reduce 
DOPAC overflow to control levels. Taken together, these results indicate that D2 
priming facilitates DOPAC overflow.   No other significant differences were found 
between groups. Analysis of the significant main effects revealed that there were 
significant changes in DOPAC over the different time points, and amphetamine 
significantly increased DOPAC compared to rats treated with saline.  
 
 
Table 3  DOPAC Microdialysis.  DOPAC results from microdialysis presented as an 
average concentration for each group following adult drug treatment (AMPH or saline).  
Values are DOPAC concentrations in picograms.  A * denotes a significant difference 
from saline-treated control animals (SSS). 
 
Group 
Abbreviation 
Mean 
Concentration 
Q1A 128.09* 
Q1S 96.54 
QEA 90.22 
QES 145.56* 
QSA 81.66 
QSS 321.53 
S1A 80.79 
S1S 113.34 
SEA 89.12 
SES 135.92 
SSA 80.02 
SSS 87.18 
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Norepinephrine Overflow 
 A four-way repeated measures ANOVA revealed a significant main effect of time 
point F(8,80) = 2.20, p<0.026, three significant two-way interactions:  time point x 
neonatal treatment F(1,80) = 5.37, p<0.023, time point x antagonist treatment F(2,80) = 
6.83, p<0.002, time point x adult drug treatment F(1,80) = 8.35, p<0.005 and a 
significant four-way interaction of time point x neonatal treatment x antagonist treatment 
x adult drug treatment F(2,80) = 3.53, p<0.034.  Post hoc analysis of the significant four-
way interaction revealed that rats given neonatal quinpirole treatment, saline as their 
antagonist drug treatment, and amphetamine in adulthood produced a significant 
increase in NE overflow at 80, 100, and 120 min post drug treatment, data shown in 
figures 10 and 11. Interestingly, saline-treated controls demonstrated significantly 
greater levels of norepinephrine at the 20 and 40 minute time points following drug 
administration, but this may also been due to unstable baseline in this group (data not 
shown). Overall, amphetamine treatment without antagonism produced a significant 
200% increase in NE levels at 80, 100, and 120 minutes post drug treatment in the 
nucleus accumbens core compared to controls, consistent with previous work 
(McKittrick and Abercrombie 2007).  Antagonist treatment with either SCH23390 or 
eticlopride blocked the effects of amphetamine on NE with levels equal to saline treated 
controls (Group SSS).   
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Figure 8  Norepinephrine overflow in subjects treated with SCH23390.  All groups 
demonstrated significantly lower levels of norepinephrine for the first 60 minutes post 
drug as compared to saline-treated control subjects.  At 100 minutes post drug 
treatment, groups SSA, QSA and QSS exhibited higher levels of norepinephrine than 
saline-treated control subjects.  Arrows represent dosage of amphetamine in mg/kg 
administered at each time point. Data are represented by percentage of baseline +/- 
SEM.  A * represents a significant difference from saline-treated control subjects (SSS). 
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Figure 9  Norepinephrine overflow in subjects treated with eticlopride.  Groups SSA and 
QSA exhibited significantly higher levels of norepinephrine compared to control 
subjects.  Group QEA exhibited significantly higher levels of norepinephrine compared 
to control groups.  No other significant differences were found.   Arrows represent 
dosage of amphetamine in mg/kg administered at each time point. Data are represented 
by percentage of baseline +/- SEM.  A * represents a significant difference from saline-
treated control subjects (SSS). 
 
Homovanillic Acid Overflow 
 A 2 x 2 x 3 x 9 revealed no main effects or interactions of drug treatment in the 
levels of homovanillic acid (HVA) during baseline or after drug treatment.   
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CHAPTER 4 
 
DISCUSSION  
 
 
 The results of this study indicate several important findings.  First, neonatal 
treatment with the D2/D3 receptor agonist quinpirole enhanced sensitization to 
amphetamine in adulthood. Second, neonatal quinpnirole treatment also enhanced the 
dopaminergic response to amphetamine in adulthood in the nucleus accumbens core. 
Third, it appears that both the D1 and D2 receptors are differentially involved in 
amphetamine-induced sensitization.  Based on findings that D2 primed animals 
exhibited an increased locomotor response and dopamine overflow in a brain area 
associated with drug reward, this study indicates that enhancing dopamine D2 receptor 
sensitivity enhances the behavioral and dopaminergic response to amphetamine, that 
presumably increases the rewarding effect of the drug in D2 primed animals. This is 
consistent with previous studies that have shown neonatal quinpirole treatment 
produces a more robust sensitization to the psychostimulant nicotine in adolescence 
and adulthood and produces a more robust dopaminergic response to amphetamine in 
adulthood, that is consistent with the effects reported here, because both amphetamine 
and nicotine are in the psychostimulant drug family (Perna et al. 2008, Cope et al. 
2009).   
In terms of the roles of D1 and D2 receptors, although both D1 and D2 
antagonism blocked amphetamine sensitization in males and dopamine overflow, 
pretreatment with the D1 receptor antagonist SCH-23390 was more effective in 
producing a reduction in locomotor activity in males and dopamine overflow than the 
D2-like receptor antagonist eticlopride.  Pre-amphetamine treatment with the D1 
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antagonist SCH 23390 blocked both locomotor sensitization to amphetamine as well as 
accumbal dopamine overflow, consistent with our hypothesis. Previous work has shown 
that D1 receptors are necessary for the induction of behavioral sensitization (Vezina 
1996).  Results here confirm that the blockade of the D1 receptor with SCH23390 is 
sufficient to prevent amphetamine-induced behavioral sensitization. It has been 
postulated that induction of enduring enhancements in the ventral tegmental area (VTA) 
induced by amphetamine involve the somatodendritic release of dopamine and its 
action at dopamine D1 receptors.  Dopamine D1 receptors in the VTA appear to be 
positioned such that they can exert a critical influence on the initiation of changes in the 
reactivity of accumbal dopaminergic neurons that lead to a long-term sensitized 
locomotor response as well as dopaminergic response from the nucleus accumbens 
(Vezina 1996).  The release of both GABA and glutamate into the ventral tegmental 
area has also been shown to be modulated by D1 receptors (Cameron and Williams 
1993, Kalivas and Duffy 1995), and both of these neurotransmitters have been shown to 
influence the induction of behavioral sensitization to psychostimulants (Wolf et al. 1994).  
Thus, the induction of sensitization may depend on D1 mediated release of 
neurotransmitters in addition to dopamine.  The drug reward pathway including the 
ventral tegmental area and nucleus accumbens are represented in figure 10. 
 70 
 
 
Figure 10  Schematic of the reward pathway involved in addiction.  Figure modified from 
NIDA Notes, 1996.  
 
The inhibitory action of dopamine has been shown to be enhanced in 
psychostimulant-sensitized animals and that this effect is also mediated by D1-like 
receptors (O'Donnell and Grace 1994).  For example, GBR12909, a dopamine transport 
(DAT) inhibitor, showed no effect on the synaptic action of dopamine following 
psychostimulant treatment indicating that the enhancement of the presynaptic inhibition 
is not likely to be attributed to downregulation of dopamine transporter activity (Beurrier 
and Malenka 2002).   Rather, this change in presynaptic inhibition appears to be caused 
by a modification of the number of presynaptic D1-like receptors. Past results have 
shown, for instance, that chronic administration of the dopamine reuptake inhibitor 
cocaine results in increased inhibitory action of D1 agonists on single-unit responses of 
nucleus accumbens neurons (Henry and White 1991).  These data suggest that the 
effect of D1 receptors in behavioral sensitization are the result of increased postsynaptic 
inhibition.  This theory is supported by the decreased locomotor response and of 
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dopamine overflow following treatment with the D1 receptor antagonist SCH23390.  The 
reduction of dopaminergic overflow in this study produced by SCH 23390 was not 
accompanied by a comparable increase in the dopamine metabolites DOPAC or HVA, 
indicating that the change occurs outside of the metabolism of dopamine and supports a 
change in the receptor functionality.   
 Although Vezina postulated that induction of behavioral sensitization requires the 
D1 but not the D2 receptor (1996), results here indicate a role of the D2 receptor in 
behavioral sensitization.  However, this may be the result of differences in design and 
methodology. Vezina (1996) employed a pretreatment of SCH23390 for D1 antagonism 
or eticlopride, spiprerone or sulpiride for D2 antagonism followed by amphetamine or 
saline treatment up to 1 hour later, and sensitization was tested by amphetamine 
challenge 1-3 weeks later.  In the present study, antagonist administration was followed 
by amphetamine administration by only 10 mins, that could be related the time course 
and action of eticlopride and its efficacy to block not only D2 subtypes but D3 receptor 
subtypes.  Additionally, in the present study amphetamine was administered every other 
day for a total of seven exposures.  In the Vezina (1996) study, amphetamine was 
administered at a dose of 1.0 mg/kg once every 3rd day for five injections.  Though the 
doses of amphetamine, eticlopride, and SCH23390 were the same in both studies, it is 
likely that the differences in experimental design may account for the differences in 
effects at the D2-like receptors in these studies.  It is not possible to exclude a possible 
impact of the D3 receptor since both quinpirole and eticlopride have possible effects at 
the D3 receptor in addition to the D2 receptors within this study.  Vezina (1996) 
suggested that D2 receptors did not have a role in sensitization to amphetamine and 
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showed similar results using three dopamine D2 antagonists, two of that are more 
selective to the D2 receptor than eticlopride.  Interestingly, eticlopride treatment to rats 
neonatally treated with saline resulted in locomotor activity levels that were similar to 
non D2-primed animals treated with amphetamine as seen in figures 2b and 3b.  
Dopamine D2-primed animals receiving eticlopride and amphetamine resulted in a 
locomotor profile very similar to that of non D2-primed subjects receiving eticlopride 
alone.  Such findings suggest that systemic eticlopride can attenuate the locomotor 
effects of amphetamine, but that eticlopride treatment alone given in adulthood creates 
a change in dopamine receptors that results in behavioral changes similar to those seen 
from neonatal priming.  Interestingly, past studies have shown that eticlopride (0.6 
mg/kg) potentiates dopamine release by amphetamine using functional MRI as well as 
in locomotor activity (Tanabe et al. 2004; Chen YC et al. 2005), although in the latter 
study, eticlopride was infused into the VTA.   There is no doubt that differences in 
administration routes (i.e. intrabrain administration versus systemic ip injection) and 
dosages may account for differential results, and, in fact, it suggests that the effects of 
systemic administration of eticlopride on dopamine overflow is fundamentally different 
from direct infuction into brain areas.    
Interestingly, there were sex differences in the response to eticlopride. Pre-
treatment with eticlopride blocked sensitization to amphetamine more effectively in 
females than in males but completely blocked amphetamine‟s effects on accumbal 
dopamine overflow equally across both sexes. This is inconsistent with our hypothesis 
but poses an interesting finding in that this is the only study to analyze the effects of 
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systemic treatment with the D2/D3 antagonist eticlopride on amphetamine sensitization 
and its effects on dopamine overflow.  
Amphetamine administration significantly increased turning behavior in males 
and females, an effect that was blocked by both D1 and D2 antagonist treatment, 
though D1 blockade was more effective, similar to results with horizontal activity.  This 
behavioral effect also may be the result of a greater density of striatal dopamine D1 
receptors and turning behavior has been shown to be a valid test of striatal function.  
Amphetamine action on neurotransmission is complex.  First, amphetamine 
uptake by DAT is required.  Second, amphetamine then inhibits the activity of vesicular 
monoamine transporter (VMAT) resulting in an increase in non-vesicular cytosolic 
neurotransmitter concentrations.  This increase in neurotransmitter results in reverse 
transport of the neurotransmitter via membrane-bound transporters (Sulzer et al. 1993; 
Sulzer et al. 1995).  Quantification of neurotransmitters by microdialysis following 
amphetamine administration is a result of overflow rather than vesicular release of the 
neurotransmitter.   Results showed amphetamine-induced overflow of dopamine in the 
nucleus accumbens (core) in rats was greater in rodents repeatedly treated with 
quinpirole during the postnatal development period (Nowak et al. 2001).  
It is hypothesized that the underlying mechanism of this effect is related to 
several factors. First, amphetamine produced a significant increase in dopamine 
overflow. Second, amphetamine has been shown to produce a subsensitization of 
presynaptic D2 autoreceptors in the VTA. Third, neonatal quinpirole produces 
supersensitization of postsynaptic D2 receptors resulting in an increased dopaminergic 
response to amphetamine (Nowak et al. 2001).  This increased dopaminergic response 
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presumably results in a more robust behavioral activation to the drug. There is another 
complex caveat to this mechanism. Based on the fact that quinpirole is a D2/D3 agonist, 
it binds to and activates both the presynaptic inhibitory D2 autoreceptor as well as the 
postsynaptic D2 receptor. Past work has shown that acute quinpirole treatment actually 
produces a decrease in dopamine overflow (Nowak et al. 2001) in the dorsal striatum, 
and this is presumably due to its action at the autoreceptor. Therefore, it is assumed 
that quinpirole primes both the D2 inhibitory autoreceptor and the D2 postsynaptic 
receptor with roughly equal affinities. A critical action relative to the results observed 
here is that amphetamine produces subsensitivity of the inhibitory D2 autoreceptor. 
Therefore, supersensitization of the postsynaptic receptor as is produced by neonatal 
quinpirole is the most plausible explanation of the mechanism observed in the present 
study.    
The mechanism of D2 receptor supersensitivity, or D2 priming, is unknown. 
When D2 receptors are activated, a G-protein coupled receptor (GPCR), like the 
dopamine-bound D2 dopamine receptor, binds a trimeric G-protein and catalyzes the 
exchange of GTP for GDP at the alpha subunit of the G-protein that leads to the 
dissociation of GTP bound alpha subunit.  This dissociation allows the freed dimer to 
regulate activity of cellular effector molecules.  Signal termination is mediated by the 
GTPase activity intrinsic to the alpha subunit.  The GTPase hydrolyzes the bound GTP 
to GDP allowing the subunit to reassociate with the dimer (Ross and Wilkie 2000).  
GTPase activity of the alpha subunit and thereby the signal termination of the GPCR 
can be enhanced by members of a family of proteins called regulators of G-protein 
signaling (RGSs) (Berman and Gilman 1998, Ross and Wilkie 2000).  One such protein, 
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RGS9, has a splice transcript RGS9-2 that is confined to the striatum (Thomas et al. 
1998).  Mice with a null mutation in the RGS9 gene showed heightened locomotor 
responses to cocaine and related psychostimulants, whereas viral-mediated 
overexpression of RGS9-2, but not RGS4, in rat striatum specifically reduced locomotor 
responses to D2 receptor agonists (Rahman et al. 2003).  As mentioned above in the 
introduction, we have shown that RGS9 is significantly downregulated in D2 primed 
animals as compared to non D2-primed animals (Maple et al. 2007) in several heavily 
innervated dopaminergic brain areas, including the striatum, nucleus accumbens, and 
frontal cortex. Therefore, it appears that regulation of D2 receptor signal transduction is 
lessened in animals neonatally treated with quinpirole, likely resulting in an overall 
increased response from this family of receptors. Modifications of downstream proteins 
including, but not limited to, the RGS family of proteins may help to account for the 
modifications of the cascade resulting in greater or prolonged dopaminergic effect 
following amphetamine administration. However, it should be noted that no second 
messenger system has been identified to fully account for the supersensitization 
following neonatal quinpirole treatment. 
Amphetamine has been shown to produce an additive effect on extraneuronal 
dopamine levels in both the striatum and nucleus accumbens core in rats neonatally 
treated with quinpirole (Nowak et al. 2001, Cope et al. 2009).  This additive effect may 
result from amphetamine actions mediated by both the D1 and D2 receptors.  In this 
study we attempted to elucidate the roles of each receptor.  Results here suggest the 
D1 receptor does play a role in regulating the extraneuronal levels of dopamine in the 
nucleus accumbens core.  However, eticlopride blockade of the D2 receptor also 
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attenuates the effects of amphetamine on extraneuronal dopamine in the nucleus 
accumbens.  Such an impact of singular receptor blockade implicates mediation by 
synergistic effects of the D1 and D2 receptors. It has been shown that concomitant 
stimulation of the D1 and D2 receptors is required under normal conditions for many 
actions of dopamine, a phenomenon referred to as D1/D2 synergism (Gershanik et al. 
1983, La Hoste et al. 1996).  This type of receptor interaction is representative of an 
extreme form of synergism in that the effect of two combined drugs exceeds the 
algebraic sum of their two effects.  In this form, two drugs (e.g. D1 and D2 agonists) 
potentiate the effects of the other and each is ineffective without the other based on the 
activation of both dopamine receptor subtypes.  It is the concurrent activation of both 
receptor subtypes that results in the synergistic effects.  In terms of amphetamine, an 
indirect dopamine agonist, administration results in an increased dopamine release 
resulting in stimulation of D1 and D2 receptors postsynaptically, an idea supported in 
work showing that blockade of presynaptic autoreceptors does not impact this D1 and 
D2 interaction (Shi et al. 1997). 
 Synergism is evident in the control of motor behavior. For example, reserpine-
induced akinesia can be reversed by combined but not separate administration of a 
selective D1 or selective D2 agonist.  Increases in locomotion and motor stereotypy 
elicited by the indirect dopamine agonists apomorphine and amphetamine can be 
blocked by either a selective D1 or D2 antagonist (Lewis et al. 1983, Martres et al. 
1992).  The results of this study provide further evidence that there is such interplay 
between dopamine receptors given the ability of either D1 or D2 antagonist treatment to 
prevent amphetamine-induced increases in locomotion.  It must be noted that basal 
 77 
 
levels of endogenous dopamine may provide sufficient D1 tone to synergize with an 
exogenous D2 agonist.  Administration of a D1 agonist alone does not elicit motor 
stereotypy, whereas administration of a D2 agonist alone does (White et al. 1988).   
 Following selective destruction of central dopaminergic neurons with the 
neurotoxin, 6-hydroxy-dopamine (6-OHDA), or prolonged depletion of monoamines with 
reserpine, there is a increased expression of striatal D2 receptors and animals become 
supersensitive to D1 or D2 agonists (La Hoste et al. 1993a).  Accompanying the agonist 
supersensitivity is a complete breakdown of requisite D1/D2 synergism.  Functions that 
previously required concomitant D1/D2 stimulation can be mediated by independent 
stimulation of either D1 or D2 receptors.  This is true for stereotyped motor behavior, 
inhibition of striatal neuron firing, and striatal c-fos expression (La Hoste et al. 1993b).  
D1/D2 synergism may then play a role in amphetamine induced behavioral sensitization 
but does not account for effects following D2 receptor priming as it is expected that such 
priming would break down the synergistic mechanism.  A breakdown in D1/D2 
synergism as a result of priming is thought to be the result of a lack c-fos expression in 
the striatum following D2 agonist treatment.  The absence of c-fos causes a change in 
the downstream cascade of gene expression that persists for at least 8 hours, a time 
consistent with that of causal events leading to increased sensitivity and a breakdown in 
D1/D2 synergism (LaHoste et al. 1993b). 
 Functional modifications of dopamine receptors have been implicated to be 
critical in the process of sensitization with regard to psychostimulants including 
amphetamine, nicotine, and cocaine (Kalivas and Duffy 1993; Kalivas et al. 1993; 
Vanderschuren and Kalivas 2000).  Such a functional change has been specified to 
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exist in the mesocorticolimbic pathway, the pathway implicated in behavioral 
sensitization (Kalivas et al. 1993).  
Both dopamine D1 and D2-like receptors in the NAcc as well as glutamate 
NMDA and AMPA receptors located on medium spiny neurons in the VTA are primary 
targets for altered neurotransmission following amphetamine or cocaine treatment 
(Montague et al. 2004, Hyman et al. 2006).  When animals are sensitized to a drug, 
prior research suggests, dopamine D1 receptor supersensitivity occurs in the nucleus 
accumbens as a result of the upregulation of the cAMP pathway (Nestler and 
Aghajanian 1997).  The blockade of dopamine D1 receptors in the present study 
prevented amphetamine-induced sensitization, an effect that may be explained by 
changes in the cAMP pathway.  This cellular event may impact downstream G-protein 
coupling and result in an upgregulation of adenylyl cyclase and protein kinase A signals.  
D1 dopamine receptor-mediated cellular signaling cascade could then enhance the 
phosphorylation of the transcription factor cAMP response element binding protein 
(CREB) and the expression of immediate-early genes, such as Fos and Jun (Nestler 
2002, Waters et al. 2003).  Induction of expression of those genes is rapid and mostly 
transient and invokes subsequent gene expression (Zhang et al. 2005).  For example, 
activation of CREB by phosphorylation is a common neuronal adaptation in the nucleus 
accumbens to psychostimulants (Impey et al. 2004).  Previous studies suggest that 
drug-induced CREB activation/phosphorylation in the nucleus accumbens constitutes a 
negative feedback mechanism that dampens behavioral sensitivity to subsequent drug 
exposure (Carlezon et al. 2005).   
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Further, the accumulation of ΔFosB in the nucleus accumbens is a universal 
phenomenon following chronic exposure to abused drugs (Nestler et al. 1995).  Over 
expression of ΔFosB in the nucleus accumbens increases the behavioral response to 
cocaine and amphetamine and the amount of ΔFosB accumulation in the nucleus 
determines the duration and intensity of drug-induced behavioral sensitization (McClung 
et al. 2004). Blockade of the D1 receptor with SCH23390 has been shown to attenuate 
the induction of fos proteins but D2 receptor antagonist treatment increased fos related 
proteins levels seen following amphetamine treatment (Nestler et al. 1995).  In terms of 
the molecular mechanism underlying dopaminergic receptor involvement in behavioral 
sensitization, fos proteins, including ΔFosB, appear to play a larger role in changing the 
downstream gene expression following drug exposure.  Results involving the fos 
proteins appear to indicate that the D1 receptor plays the mediating role in sensitization.  
Thus, modulation of dopamine receptors through antagonism may reduce the 
amphetamine-induced increases ΔFosB, allowing for a potential modulation of 
behavioral sensitization. A future study in this laboratory will analyze the expression of 
delta FosB within this model. 
  The results of this study support the theory that both D1 and D2 receptors have 
a role in amphetamine behavioral sensitization.  Further, D2 primed animals appear to 
have an increased sensitivity at the D2 receptor such that the coupled treatment of 
quinpirole and eticlopride results in a stimulated response comparable to animals 
treated with amphetamine regardless of neonatal drug treatment.  This may support the 
idea that D2 priming produces an autoreceptor subsenstivity that enhanced the 
dopaminergic response similar to that of amphetamine (Kostrzewa et al. 2008).  As 
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expected, dopamine D1 antagonist treatment in D2-primed animals was more effective 
in reducing locomotor activity in female rats than male rats compared to saline treated 
control subjects because female rats are more susceptible to antagonist effects than 
males (Schindler and Carmona 2002).   This supports previous work showing that 
females are more susceptible to the effects of dopamine D1 receptor blockade than are 
males, although D2 blockade using eticlopride has been shown to be effective at 
blocking cocaine sensitization in at least one past study (Schindler and Carmona 2002), 
whereas in the present study eticlopride was not effective at blocking amphetamine 
sensitization in adult females. This points to a possible sexual dimorphism not only in 
the response to antagonists but in the combination of dopaminergic antagonists with 
amphetamine.  
With regard to D2 receptors, increased antagonist susceptibility may arise from 
dopaminergic fluctuations related to estrogen levels and stages of the estrus cycle.   In 
females, estrogen acts to inhibit GABA neurons in the striatum and accumbens resulting 
in increased dopamine function.  Estrogen also acts to enhance dopamine release by 
downregulating D2 receptor function (Becker 1999).  Though no effects of estrus cycle 
stage were found associated with sex differences in locomotor activity in the present 
study, that may be the result of insufficient sample size in each stage of estrus.  
However, animals were treated every other day for the duration of sensitization; 
therefore, female subjects should have been administered adult drug treatment and 
antagonist across all stages of the cycle. 
 D2 primed animals treated with eticlopride exhibited no difference relative to 
saline treated controls on the horizontal activity measure.  However, non D2-primed 
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females treated with eticlopride and saline exhibited an increase in locomotor activity as 
compared to saline- treated control subjects. This is likely the result of presynaptic 
autoreceptor blockade that results in a disinhibition of dopamine release, thereby 
stimulating additional dopamine release and increasing locomotor activity (Goldwert et 
al. 2006).  Female rats showed a greater reduction in activity following SCH23390 
treatment as compared to males, consistent with past work (Schindler and Carmona 
2002).  This difference in D1 response may also be the result of dopaminergic changes 
associated with estrogen (Becker 1999).  However, the nucleus accumbens plays a 
significant role in behavioral sensitization and males show a higher density of D1 
receptors in the nucleus accumbens (Andersen et al. 1997).  This difference in receptor 
density may also account for an increased impact in females.  Less dense populations 
of receptors would likely result in a greater occupancy of receptors by a lower dose of 
antagonist and may account for females responding in a more significant way to 
receptor blockade.   As expected, males showed a less robust sensitization response to 
amphetamine compared to females. This expectation was based on previous work that 
has shown that the D1 receptor plays a more important role in amphetamine 
sensitization, although there are no data on sex differences in the roles of D1 and D2 
receptors in amphetamine sensitization.  
  In terms of behavioral sensitization, past work has shown that females exhibit 
more robust sensitization than do intact males to amphetamine (Camp and Robinson 
1988, Becker 1999, Perna et al. 2007, Cope et al. 2008).  We hypothesized that female 
rats would be more sensitive to the antagonism treatments of both D1 and D2 
receptors. One of the more important and interesting effects reported here was that 
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blockade of the D1 receptor completely blocked sensitization to amphetamine in both 
males and females, at least implying D1 receptor function is similar across the two 
sexes in terms of amphetamine sensitization. In contrast, blockade of the D2 receptor 
by eticlopride was more effective at blocking amphetamine sensitization in males as 
compared to females, suggesting a sex difference in D2 function. One issue here is that 
eticlopride is only 3-4 fold more selective for the D2 receptor subtype as compared to 
the D3 receptor subtype (Claytor et al. 2006). Thus, this may be reflective of sex 
differences of not only the D2 but D3 receptor subtype of the D2 receptor family. A more 
selective D2 receptor antagonist may be able to more effectively ascertain the roles of 
the D2 and D3 receptors in males and females.  In other work from this lab, both D2 and 
D3 receptor subtypes have been shown to be involved in the locomotor activating 
effects of nicotine (Sheppard 2008).  A second issue here, however, is that sex 
differences in D2 receptor function have been shown. Females demonstrate a higher 
amount of locomotor activation when D2 receptors are activated by an agonist 
(Szumnlinski et al. 2000, Schindler & Carmona, 2002) but locomotor depression to D2 
antagonism, although this study used adolescents (Sheppard et al. in press). 
Additionally, age differences in the development of dopamine receptors prevalent in the 
striatum and nucleus accumbens have been shown (Andersen & Teicher, 2000). 
Females demonstrate a more stable number of D2 receptors throughout development, 
whereas males exhibit a lower amount of D2 receptors in early adolescence with the 
number peaking in mid-adolescence before being reduced to equivalent numbers of D2 
receptors as females in adulthood. This may have repercussions as to the adult 
dopamine function as well, but this has yet to be delineated. Regardless, these results 
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support past work that sex differences in D2 function and D2 receptor development 
exist. 
There are no results from DOPAC or HVA samples that indicate increased 
dopaminergic overflow is the result of a change in dopamine metabolism.  D2-primed 
animals treated with saline as well as primed animals treated with SCH23390 and 
amphetamine revealed a significantly higher level of DOPAC in microdialysate samples 
as compared to saline treated controls.  These results suggest that the D2 priming 
related increase in DOPAC is not related to D1/D2 synergism, as said increase can not 
be fully attenuated following D1 receptor blockade.  Additionally, at 40 minutes post 
drug treatment, non-D2-primed animals treated with SCH23390 show elevations in 
DOPAC release.  This may indicate an increase in dopamine catabolism that resolves 
at 60 minutes potentially indicating a freeing up of previously bound receptors or a self-
resolving mechanism following dopamine catabolism.  This follows the results that 
SCH23390 can increase dopamine overflow due to its action on presynaptically located 
D1 receptors (Egilmez et al. 1995). Thus, it is then likely that changes occur within 
presynaptic receptor functionality rather than dopamine metabolism following release. 
 Maybe the most important aspect of the present study is that these results are 
consistent with clinical findings. Schizophrenic patients, using a single photon emission 
computerized tomography (SPECT), have shown increased striatal dopamine release in 
response to an amphetamine challenge as compared to healthy matched control 
subjects (Laruelle et al. 1996, Abi-Dargham et al. 1998).  Increased dopaminergic 
transmission was also associated with behavioral consequences (e.g. worsening or 
emergence of psychotic symptoms).  The effects of amphetamine on subjects were not 
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attributable to peripheral effects of the drug.  More specifically, increased striatal 
dopamine release following amphetamine administration is associated with the D2 
receptor sensitivity (Laruelle et al. 1996, Abi-Dargham et al. 1998).  These studies 
present a clinical correlation for the findings of this study in terms of increased 
dopaminergic overflow and locomotor findings.  Taken together, these results confirm 
the involvement of the dopamine D2 receptor in terms of modeling psychosis, and more 
specifically, schizophrenia. 
 In the current study, amphetamine was shown to significantly increase 
norepinephrine overflow in both D2-primed and non D2-primed male and female rats, 
although neonatal quinpirole treatment did not enhance this effect.  This result is 
consistent with work by McKittrick and Abercrombie (2007) who have shown systemic 
amphetamine administration resulted in a significant increase in norepinephrine 
overflow in the nucleus accumbens.  Treatment with either D1 or D2 antagonist blocked 
the amphetamine-induced increase in norepinephrine overflow in the nucleus 
accumbens.   
It has been shown that norepinephrine overflow in the rat nucleus accumbens is 
under the opposing influence of stimulatory dopamine D1 and inhibitory dopamine D2 
receptors (Vanderschuren et al. 1999). The D2 antagonist sulpiride has been shown to 
strongly increase norepinephrine overflow in the nucleus accumbens, whereas the D1 
antagonist SCH23390 did not reduce norepinephrine overflow (Vanderschuren et al. 
1999).  Results of this study similarly show that SCH23390 does not significantly reduce 
norepinephrine as compared to control subjects; however, the D2-like antagonist 
eticlopride does not appear to increase norepinephrine overflow.  Inhibitory dopamine 
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D2 receptors have been shown to regulate norepinephrine overflow, as opposed to the 
enhancing effects of the dopamine D1 receptor in an in vitro study using superfusion 
techniques (Vanderschuren et al. 1999).  Results here support that idea as eticlopride 
as a D2 like antagonist blocked norepinephrine overflow in the nucleus accumbens.  It 
is important to note that effects of eticlopride may not be limited to the D2 receptor, as 
eticlopride also has significant affinity for the D3 receptor.  The limitations of this study 
do not allow a complete understanding of any potential involvement at D3 receptors.   
The combined treatment of quinpirole and amphetamine result in an increased 
norepinephrine overflow at the 80, 100, and 120 minute time points.  If released 
endogenous dopamine tonically inhibits norepinephrine overflow in the nucleus 
accumbens through the stimulation of D2 receptors, then D2 primed animals, as well as  
non D2-primed animals treated with amphetamine should have similar norepinephrine 
levels to saline controls an idea supported by the data.  Dopamine D2 receptors are 
located near active zones formed by dopamine and norepinephrine terminals, whereas 
dopamine D1 receptors are located more distally from the site for dopamine overflow 
(Sesack et al. 1994, Hersche et al. 1995).  It may be that dopamine released from 
mesolimbic neurons preferentially interacts with D2 receptors located closer to the 
terminal of release (Vandershuren 1999).  If such a proximal relationship prevails, 
blockade of the D2 receptor by eticlopride would then inhibit norepinephrine overflow in 
the nucleus accumbens.  Dopamine D2-primed animals treated with amphetamine as a 
result of the increased dopamine overflow would activate both D1 and D2 receptors 
resulting in a net increase in norepinephrine overflow.  Dopamine D2 receptor priming 
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alone would not be expected to enhance norepinephrine overflow but rather to inhibit 
such overflow.     
Conclusions 
 Dopaminergic dysfunction is implicated in underlying several mental illnesses 
including schizophrenia, obsessive-compulsive disorder, and bipolar disorder.  Mental 
illnesses are often comorbid with substance abuse disorder leading to a dual diagnosis.  
Such a dual diagnosis complicates treatment and may impact the overall effectiveness 
of pharmacological interventions.  Using a D2 priming model to mimic dopamine D2 
receptor dysfunction in mental illness, changes in receptor sensitivity result in changes 
in amphetamine-induced locomotor response and dopamine overflow in the nucleus 
accumbens.  Results of this study are that D2 priming enhanced the dopaminergic 
response to amphetamine in adulthood, an effect alleviated by blockade of either D1 or 
D2 receptors.  Second, changes in D2 receptor sensitivity may increase the positive 
reinforcing effect of a psychostimulant drug in adult animals.  Third, D1 receptor 
blockade was more effective in reducing locomotor activity in males and dopamine 
overflow than D2 receptor blockade b eticlopride.  Fourth, females are more sensitive to 
the effects of D1 receptor blockade than males.   
If supersensitization is a key aspect of psychosis, these changes may represent 
a mechanism toward the increased abuse of drugs in humans suffering from these 
psychotic disorders.  Blockade of dopamine D2 receptors results in patterns of 
locomotor activity and dopaminergic overflow similar to that seen from amphetamine 
administration, likely a result of presynaptic autoreceptor inhibition.   Dopamine D1 and 
D2 receptors differentially play a role in amphetamine-induced sensitization.  Dopamine 
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D1 receptor blockade is more effective at preventing locomotor sensitization than D2 
receptor blockade.  This may indicate a primarily motor involvement of the D1 receptor 
family in terms of behavioral sensitization rather than involvement in the rewarding 
properties of amphetamine.  Conversely, dopamine D2 receptor may play less of a role 
in the activating effects of amphetamine, but when antagonist to this receptor are given 
systemically, they appear to produce a different effect on dopamine function than when 
infused. Precisely the mechanism behind this is not known and outside of the scope of 
the present work but opens up an interesting area of research. All antipsychotic drugs 
antagonize the D2 receptor (Tollefson 1996) and are obviously given systemically. 
Thus, it appears that the route in that this drug is given may have important implications 
relative to its effects on neurochemistry and specifically, dopamine function.   
 It is unclear what impact sex differences have in this interaction.  Females were 
more susceptible to the effects of dopamine antagonists than males.  Further 
experimentation is required to clearly elucidate sex differences in D2 primed animals 
and how this may be related to hormonal fluctuations.  Clinical results have shown that 
female patients are more sensitive to the effects of abused drugs (Carroll et al. 2004), a 
result supported here.  Many such measurements of response to a drug in a clinical 
setting are subjective and cannot be modeled in animals.  Animal models are then 
limited in allowing a full understanding of underlying sex differences in a dual diagnosis.  
Dopaminergic dysfunction may underlie mental illnesses and increases in dopamine D2 
sensitivity may represent a mechanism for vulnerability to psychostimulant abuse, 
particularly in terms of comorbidity.  
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 Substance abuse in schizophrenics carries consequences that further impact 
schizophrenic patients. Results of the current study correlate with clinical findings that 
amphetamine increases dopaminergic transmission in schizophrenic patients, and that 
increases in dopaminergic transmission are associated with a worsening of behavioral 
symptoms of schizophrenia.  This model may then allow for further exploration of 
mechanism(s) that result in a greater incidence of drug use, particularly 
psychostimulants, in schizophrenics compared to the general population.   
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